<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.3">
  <?properties open_access?>
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Rheumatol Ther</journal-id>
      <journal-id journal-id-type="iso-abbrev">Rheumatol Ther</journal-id>
      <journal-title-group>
        <journal-title>Rheumatology and Therapy</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">2198-6576</issn>
      <issn pub-type="epub">2198-6584</issn>
      <publisher>
        <publisher-name>Springer Healthcare</publisher-name>
        <publisher-loc>Cheshire</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">34519965</article-id>
      <article-id pub-id-type="pmc">8572231</article-id>
      <article-id pub-id-type="publisher-id">365</article-id>
      <article-id pub-id-type="doi">10.1007/s40744-021-00365-1</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Review</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Differentiating Psoriatic Arthritis from Osteoarthritis and Rheumatoid Arthritis: A Narrative Review and Guide for Advanced Practice Providers</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Saalfeld</surname>
            <given-names>William</given-names>
          </name>
          <address>
            <email>William.Saalfeld@nebraskaarthritis.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mixon</surname>
            <given-names>Amanda M.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zelie</surname>
            <given-names>Jonna</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lydon</surname>
            <given-names>Eileen J.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <aff id="Aff1"><label>1</label>Arthritis Center of Nebraska, 3901 Pine Lake Road, Suite 120, Lincoln, NE 68516 USA </aff>
        <aff id="Aff2"><label>2</label>Arthritis and Rheumatology Clinic of Northern Colorado, Fort Collins, CO USA </aff>
        <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.412750.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 9166</institution-id><institution>URMC Division of Rheumatology, </institution></institution-wrap>Rochester, NY USA </aff>
        <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.240324.3</institution-id><institution-id institution-id-type="ISNI">0000 0001 2109 4251</institution-id><institution>NYU Langone Medical Center, </institution></institution-wrap>New York, NY USA </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>14</day>
        <month>9</month>
        <year>2021</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>14</day>
        <month>9</month>
        <year>2021</year>
      </pub-date>
      <pub-date pub-type="collection">
        <month>12</month>
        <year>2021</year>
      </pub-date>
      <volume>8</volume>
      <issue>4</issue>
      <fpage>1493</fpage>
      <lpage>1517</lpage>
      <history>
        <date date-type="received">
          <day>11</day>
          <month>6</month>
          <year>2021</year>
        </date>
        <date date-type="accepted">
          <day>24</day>
          <month>8</month>
          <year>2021</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Author(s) 2021</copyright-statement>
        <license>
          <ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
          <license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <p id="Par1">Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects multiple organ systems and is characterized by skin and joint manifestations. PsA is frequently undiagnosed and/or misdiagnosed, especially because of the similarities in clinical presentation shared with other arthritic diseases, including rheumatoid arthritis (RA) and osteoarthritis (OA). An accurate and timely diagnosis of PsA is crucial to prevent delays in optimal treatment, which can lead to irreversible joint damage and increased functional disability. Patients are usually seen by a number of different healthcare providers on their path to a diagnosis of PsA, including advanced practice providers (APPs). This review provides a comprehensive overview of the characteristic features that can be used to facilitate the differentiation of PsA from RA and OA. Detailed information on clinical manifestations, biomarkers, radiologic features, and therapeutic recommendations for PsA included here can be applied in routine clinical settings to provide APPs with the confidence and knowledge to recognize and refer patients more accurately to rheumatologists for management of patients with PsA.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Psoriatic arthritis</kwd>
        <kwd>Diagnosis</kwd>
        <kwd>Rheumatoid arthritis</kwd>
        <kwd>Osteoarthritis</kwd>
        <kwd>Clinical presentation</kwd>
      </kwd-group>
      <funding-group>
        <award-group>
          <funding-source>
            <institution-wrap>
              <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100008272</institution-id>
              <institution>Novartis Pharmaceuticals Corporation</institution>
            </institution-wrap>
          </funding-source>
        </award-group>
      </funding-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2021</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="FPar1">
      <title>Key Summary Points</title>
      <p id="Par2">
<table-wrap id="Taba"><table frame="hsides" rules="groups"><tbody><tr><td align="left">Psoriatic arthritis (PsA) is a complex disease characterized by inflammation of multiple clinical domains, including peripheral joints, skin and nails, axial joints, entheses, eyes, and digits</td></tr><tr><td align="left">The similarities in clinical presentation of PsA and other rheumatic diseases such as rheumatoid arthritis (RA) or osteoarthritis (OA) can make a differential diagnosis challenging; therefore, it is crucial for primary care providers, including advanced practice providers (APPs), to be aware of characteristics and criteria indicative of a diagnosis of PsA</td></tr><tr><td align="left">Characteristic features can be used to differentiate PsA from RA and OA, and early assessment, diagnosis, and treat-to-target strategies are key to the management of patients with PsA to facilitate the administration of appropriate therapy in a timely manner</td></tr><tr><td align="left">Collaboration and coordinated care are key among primary care providers, APPs, and subspecialists to ensure positive outcomes for patients, controlling symptoms and disease activity, maintaining functional ability, and improving patient quality of life</td></tr></tbody></table></table-wrap></p>
    </sec>
    <sec id="Sec1">
      <title>Introduction to Psoriatic Arthritis, Rheumatoid Arthritis, and Osteoarthritis</title>
      <p id="Par3">Psoriatic arthritis (PsA) is a chronic inflammatory heterogeneous arthritis that is associated with psoriasis, and approximately 30% of patients with psoriasis develop PsA [<xref ref-type="bibr" rid="CR1">1</xref>]. It is estimated that PsA has a prevalence rate of approximately 1&#x2013;2 per 1000 in the general population and an incidence rate of approximately 6 per 100,000 per year [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. Generally, onset of PsA occurs between ages 30 and 50&#xA0;years but can develop at any point throughout a patient&#x2019;s lifetime. The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) defined six clinical domains that can be involved with PsA: peripheral arthritis, enthesitis, dactylitis, psoriasis, psoriatic nail disease, and axial disease [<xref ref-type="bibr" rid="CR4">4</xref>&#x2013;<xref ref-type="bibr" rid="CR6">6</xref>].</p>
      <p id="Par4">Definitive diagnosis of PsA is further complicated by several arthritic conditions with similar clinical presentations. PsA is often undiagnosed and can be misdiagnosed for rheumatoid arthritis (RA) or osteoarthritis (OA), especially in a non-rheumatologic setting [<xref ref-type="bibr" rid="CR7">7</xref>&#x2013;<xref ref-type="bibr" rid="CR9">9</xref>]. RA is a chronic inflammatory arthritis typified by pain, swelling, and stiffness of the joints, particularly symmetric small-joint synovitis of the hands and feet [<xref ref-type="bibr" rid="CR10">10</xref>]. The lining of the joints is primarily affected in RA, and without adequate treatment, long-standing disease activity can result in permanent joint deformity and bone damage [<xref ref-type="bibr" rid="CR11">11</xref>]. It is estimated that RA has global prevalence and incidence rates of 246.6 and 14.9 per 100,000 in the general population, respectively [<xref ref-type="bibr" rid="CR12">12</xref>]. RA can present at any age, but peak age of onset is between ages 30 and 50&#xA0;years, and likelihood increases with age [<xref ref-type="bibr" rid="CR11">11</xref>]. OA is the most common non-inflammatory arthritic condition strongly associated with aging, and symptoms arise from deterioration of joint cartilage, which can cause changes in the bone and connective tissues of the joints [<xref ref-type="bibr" rid="CR13">13</xref>]. Additionally, erosive inflammatory OA, typically affecting the hand, is a subset of OA that can mimic common inflammatory arthritic conditions, further complicating the distinction of OA from PsA [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]; however, this subset of OA does not have an established diagnostic criterion [<xref ref-type="bibr" rid="CR16">16</xref>], and therefore it will not be treated as a separate clinical condition throughout this review. Onset of OA is usually in the late 50s [<xref ref-type="bibr" rid="CR7">7</xref>], affecting millions of people, with prevalence and incidence estimates varying depending on OA definition [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. Recently, it was estimated that 242&#xA0;million people were living with symptomatic and activity-limiting OA of the hip and/or knee globally [<xref ref-type="bibr" rid="CR19">19</xref>].</p>
      <p id="Par5">A proper diagnosis and timely treatment of PsA are essential to prevent permanent joint damage and decrease functional disability [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. Patients are often seen by various healthcare providers on their pathway to a diagnosis of PsA, including dermatologists, orthopedists, general practitioners, chiropractors, and advanced practice providers (APPs) [<xref ref-type="bibr" rid="CR22">22</xref>]. Diagnosis of PsA relies on early detection through appropriate history taking, careful examination, and clinical judgment, and APPs are in a position to see many patients with different rheumatic diseases; therefore, it is imperative that APPs are aware of and receive proper training to accurately screen for features to identify PsA.</p>
    </sec>
    <sec id="Sec2">
      <title>Statement of Literature Search</title>
      <p id="Par6">For the development of this narrative review, publications were identified by a series of searches on PubMed between September 2020 and July 2021. Search terms included &#x201C;(diagnos* OR differentiat*) AND (psoriatic arthritis OR rheumatoid arthritis OR osteoarthritis)&#x201D;; &#x201C;(biomarker OR serologic* OR marker OR genetic*) AND (psoriatic arthritis OR rheumatoid arthritis OR osteoarthritis)&#x201D;; &#x201C;(IL-17 OR IL-12 OR IL-23, OR IL-6 OR TNF&#x3B1; OR IL-1&#x3B2; OR JAK/STAT) AND (psoriatic arthritis OR rheumatoid arthritis OR osteoarthritis)&#x201D;; &#x201C;(biologic* OR DMARD*) AND (psoriatic arthritis OR rheumatoid arthritis OR osteoarthritis).&#x201D; Publications that detailed the characteristic clinical manifestations, comorbidities, pathogenesis, biomarkers, treatment recommendations, and differential diagnosis for PsA, RA, and OA were included. References that were determined to be irrelevant on the basis of the authors&#x2019; judgment were excluded from consideration. Relevant references that were cited within the publications included in this review and articles previously known by authors were considered on the basis of the criteria. This review is based on studies that were previously completed and does not contain any novel studies with human participants that were conducted by any of the authors.</p>
    </sec>
    <sec id="Sec3">
      <title>Key Clinical Features for Differential Diagnosis of PsA</title>
      <p id="Par7">The similarities in clinical presentation of PsA and other rheumatic diseases can make a differential diagnosis challenging; therefore, it is crucial for APPs to be aware of characteristics and criteria indicative of a diagnosis of PsA. Clinical evaluation based on patient history and thorough physical examination can be supported by classification criteria to assist the practitioner in recognizing the combination of clinical features unique to PsA. The Classification for Psoriatic Arthritis criteria were developed from patient data to standardize enrollment in clinical trials of PsA; they have been shown to have high sensitivity and specificity for the diagnosis of PsA and have been incorporated into clinical settings to assist practitioners in the identification of potential signs of PsA [<xref ref-type="bibr" rid="CR23">23</xref>]. These criteria require patients to present with at least one &#x201C;stem&#x201D; feature of inflammatory disease and at least three points given a numerical value to fulfill the PsA classification and could be included as part of a rheumatology referral checklist (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>Suggested rheumatology referral checklist. CASPAR Classification for Psoriatic Arthritis, CCP cyclic citrullinated peptide, CRP C-reactive protein, ESR erythrocyte sedimentation rate, RF rheumatoid factor</p></caption><graphic xlink:href="40744_2021_365_Fig1_HTML" id="MO1"/></fig></p>
      <p id="Par8">Characteristic features that can assist in a differential diagnosis are enthesitis, dactylitis, uveitis, nail dystrophy with psoriasis, and articular involvement that can vary considerably and may involve the peripheral joints and axial spine (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>) [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. Enthesitis is more common in PsA than in other rheumatic conditions and affects 35&#x2013;50% of patients with PsA [<xref ref-type="bibr" rid="CR26">26</xref>]. Enthesitis can present before arthritis symptoms in patients with PsA and may be the only musculoskeletal manifestation in early PsA; thus, imaging can be helpful to identify patients with subclinical disease when other clinical symptoms are absent [<xref ref-type="bibr" rid="CR24">24</xref>]. The most frequent areas of enthesitis are the insertion sites of the plantar fascia, Achilles tendon, lateral epicondyle of the elbow, and ligament attachments at the knee [<xref ref-type="bibr" rid="CR27">27</xref>]. Dactylitis (&#x201C;sausage&#x201D; fingers or toes) is the uniform swelling of the digits due to inflammation and affects up to 50% of patients with PsA [<xref ref-type="bibr" rid="CR28">28</xref>]. The hands and feet should be carefully examined for signs of dactylitis, which often presents as diffuse digit swelling of a finger or toe accompanied by redness of the skin, and pain [<xref ref-type="bibr" rid="CR29">29</xref>]. Dactylitis can be an indicator of disease severity; affected digits have been found to have significantly greater joint damage compared with non-affected digits in patients with early PsA [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>].<fig id="Fig2"><label>Fig. 2</label><caption><p>Clinical manifestations characteristic of psoriatic arthritis to differentiate from characteristics of osteoarthritis and rheumatoid arthritis. DIP distal interphalangeal, PIP proximal interphalangeal</p></caption><graphic xlink:href="40744_2021_365_Fig2_HTML" id="MO2"/></fig></p>
      <p id="Par9">Furthermore, the common association between PsA and psoriasis is well established. Patients with psoriasis can be screened for PsA in routine clinical settings to prevent diagnostic delays; in the majority of patients (75&#x2013;80%), psoriatic skin involvement precedes presentation of peripheral involvement, with approximately 7&#x2013;12&#xA0;years between onset of psoriasis and diagnosis of PsA [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. Additionally, the degree of severity, the amount of body area affected, and the areas of the body (e.g., scalp and nails) affected by psoriasis can increase the risk of developing PsA [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. Psoriatic nail lesions can be important in differential diagnosis, occurring in over 60% of patients with PsA, but uncommonly in RA and OA [<xref ref-type="bibr" rid="CR36">36</xref>]. Changes that involve the nail matrix are characterized by pitting, leukonychia (i.e., white discoloration), nail plate crumbling, red spots on the lunula, and trachyonychia (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>) [<xref ref-type="bibr" rid="CR37">37</xref>]. When the nail bed is affected, symptoms include salmon patch or oil spots, onycholysis, subungual hyperkeratosis, and splinter hemorrhages [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. Each nail lesion arises from different processes in the nail complex, and progression of entheseal inflammation in the distal interphalangeal extensor tendon of the nail is believed to be the cause of psoriatic nail changes seen in patients with PsA [<xref ref-type="bibr" rid="CR40">40</xref>]. Comorbid psoriasis can help substantiate a definitive diagnosis of PsA, although the presence of psoriasis alone is not sufficient to differentiate this disease, as psoriasis has been reported in RA and OA [<xref ref-type="bibr" rid="CR41">41</xref>&#x2013;<xref ref-type="bibr" rid="CR43">43</xref>]<fig id="Fig3"><label>Fig. 3</label><caption><p>Examples of characteristic psoriatic (<bold>a</bold>) nail matrix and (<bold>b</bold>) nail bed presentations (image reprinted from Kaeley GS, et al. <italic>J Rheumatol</italic>. 2021;48(8):1208-20. 10.3899/jrheum.201471 [<xref ref-type="bibr" rid="CR37">37</xref>])</p></caption><graphic xlink:href="40744_2021_365_Fig3_HTML" id="MO3"/></fig></p>
      <p id="Par10">Distinctive features of joint involvement in PsA, particularly in an early disease state, include inflammatory asymmetric monoarticular to oligoarticular distribution, possible spondylitis including sacroiliitis, and distal small-joint inflammation in the hands and feet. These elements can help discern PsA from RA, as the presentation seen with RA includes symmetric and polyarticular distribution, proximal hand and foot involvement, more tender and swollen joints, and the absence of sacroiliitis [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. Conversely, OA can present with joint involvement similar to that of PsA; however, it is non-inflammatory in nature compared with PsA and RA. Morning stiffness and/or worsening joint stiffness with inactivity is common in patients with PsA and RA, whereas joint pain and stiffness associated with OA tends to be exacerbated with activity and improves with rest [<xref ref-type="bibr" rid="CR45">45</xref>]. While involvement of distal interphalangeal joints is common in both PsA and OA, distal interphalangeal involvement in PsA is frequently associated with psoriatic nail disease and joint inflammation, compared with related bone spurs in OA [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR46">46</xref>].</p>
      <p id="Par11">It is also important to distinguish between the two major arthritis patterns in patients with suspected PsA&#x2014;peripheral and/or axial&#x2014;since the type of arthritis can impact patient disease state and treatment strategy. The majority of patients with PsA experience peripheral joint involvement, and approximately 25&#x2013;70% of patients have axial involvement [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>], depending on the definition of axial disease applied. To screen for peripheral arthritis, practitioners should evaluate patients for swelling and tenderness, which can be indicative of synovitis and inflammation, as well as commonly affected joints, such as feet and hands, knees, wrists, ankles, and shoulders [<xref ref-type="bibr" rid="CR24">24</xref>]. Axial arthritis can be an indicator of higher disease severity [<xref ref-type="bibr" rid="CR49">49</xref>] and commonly presents with slowly developing inflammatory back pain (IBP) [<xref ref-type="bibr" rid="CR50">50</xref>&#x2013;<xref ref-type="bibr" rid="CR52">52</xref>]. IBP is defined by the Assessment of SpondyloArthritis international Society as chronic back pain for at least 3&#xA0;months, with onset before the age of 40&#xA0;years, pain that causes waking during sleep, and stiffness that improves with activity [<xref ref-type="bibr" rid="CR53">53</xref>&#x2013;<xref ref-type="bibr" rid="CR55">55</xref>]. Since patients present with back pain in general medicine settings for a variety of reasons [<xref ref-type="bibr" rid="CR56">56</xref>], it is important to distinguish IBP from mechanical back pain, the latter of which is an injury or structural abnormality in the lower back [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR57">57</xref>]. Axial PsA is associated with a particularly high incidence of sacroiliitis, which can present as bilateral and symmetric, based on genetic status (HLA-B27). HLA-B27-positive status has been linked to increased inflammatory involvement in the sacroiliac joint and lumbar spine, compared with more involvement in the cervical spine seen in patients with HLA-B27-negative status [<xref ref-type="bibr" rid="CR58">58</xref>, <xref ref-type="bibr" rid="CR59">59</xref>]. An early manifestation of axial involvement associated with PsA is the formation of asymmetric syndesmophytes and paraspinal ossifications [<xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR61">61</xref>]. The presence of spondylitis and sacroiliitis can be detected in the axial skeleton using highly sensitive imaging modalities, such as the identification of characteristic bone marrow edema on magnetic resonance imaging (MRI).</p>
      <p id="Par12">The presence of comorbidities has been linked to each arthritic condition discussed here, yet differences among patient comorbidities may help distinguish PsA from RA or OA. Some comorbidities are significantly more common among patients with PsA, including inflammatory conditions, such as ulcerative colitis (1.1&#x2013;1.28%), Crohn&#x2019;s disease (1.0&#x2013;1.13%), and uveitis (7.0&#x2013;25.1%), and other metabolic conditions such as obesity (6.0&#x2013;45.0%) and diabetes mellitus (6.1&#x2013;20.2%) [<xref ref-type="bibr" rid="CR62">62</xref>&#x2013;<xref ref-type="bibr" rid="CR64">64</xref>]. Of note, patients with PsA or RA have comparable increased risk of cardiovascular disease (CVD) compared with the general population; in a real-world observational study, 10.3% and 12.3% of patients with RA or PsA, respectively, reported CVD [<xref ref-type="bibr" rid="CR65">65</xref>&#x2013;<xref ref-type="bibr" rid="CR67">67</xref>]. Comorbidities in patients with OA have been found to be similar to those with PsA, especially obesity, metabolic syndrome, and CVD [<xref ref-type="bibr" rid="CR68">68</xref>&#x2013;<xref ref-type="bibr" rid="CR72">72</xref>], but practitioners can still screen for psoriasis and uveitis to contribute to a definitive diagnosis of PsA vs OA.</p>
    </sec>
    <sec id="Sec4">
      <title>Application of Imaging Modalities for Differential Diagnosis of PSA</title>
      <p id="Par13">The use of conventional radiographs and more modern imaging modalities, such as ultrasonography (US), MRI, and computed tomography, can provide essential information to aid practitioners in the diagnosis, prognosis, and monitoring of treatment response in PsA. Imaging modalities can also aid in detecting subclinical joint and/or entheseal inflammation and/or morphological changes that may be present in patients with PsA who may not meet the Classification for Psoriatic Arthritis criteria for identification of PsA. The appropriate use of imaging techniques is essential for the accurate assessment of joint and bone damage to facilitate intervention with suitable therapy.</p>
      <p id="Par14">Traditional radiography can be particularly effective to detect and monitor the structural damage seen in PsA. In the evaluation of patients with suspected PsA, structural changes are likely seen in the hands and feet, although other joints can be involved [<xref ref-type="bibr" rid="CR73">73</xref>, <xref ref-type="bibr" rid="CR74">74</xref>]. Common radiographic changes to screen for include periostitis and new bone formation with concurrent joint damage characterized by erosions and joint space narrowing, osteolysis, subluxation, bone ankylosis, and pencil-in-cup change (Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>) [<xref ref-type="bibr" rid="CR75">75</xref>, <xref ref-type="bibr" rid="CR76">76</xref>]. Plain radiography can help visualize the joints of the spine, including the sacroiliac joints, and entheseal new bone formation; however, these changes are more common in late-stage PsA [<xref ref-type="bibr" rid="CR77">77</xref>, <xref ref-type="bibr" rid="CR78">78</xref>]. Radiographs can be used to discern suspected PsA from OA and RA (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>). Cartilage loss from OA appears as joint space narrowing with occasional sclerosis and can be diffuse, whereas changes from inflammatory arthritis are more discrete. RA can present with erosive changes on the periphery of the joint, and PsA is distinguished by proliferative findings [<xref ref-type="bibr" rid="CR79">79</xref>]. Although radiography can be useful since it can penetrate bone surface and visualize certain aspects of structural changes, it has restricted utility in imaging the soft-tissue changes seen in early stages of PsA [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR80">80</xref>]. Importantly, radiographs can appear normal at early stages of PsA, which can cause misdiagnosis and/or delays in diagnosis if other imaging modalities are not applied.<fig id="Fig4"><label>Fig. 4</label><caption><p>Characteristic radiographic features in PsA. Images from <bold>A</bold> Ritchlin CT, et al. <italic>N Engl J Med.</italic> 2017;376(10):957&#x2013;70. 10.1056/NEJMra1505557<sup>a</sup> and <bold>B</bold> Braga MV, et al. <italic>Sci Rep</italic>. 2020;10(1):11580. 10.1038/s41598-020-68456-7<sup>b</sup>. MC metacarpal head, MRI magnetic resonance imaging, PP proximal phalanx, STIR short-tau inversion recovery. <sup>a</sup>Radiographic features of PsA: <bold>a</bold> arthritis mutilans, with pencil-in-cup deformities (arrow) and marked bone resorption (osteolysis) in phalanges of the right hand; <bold>b</bold> the hand radiograph shows joint resorption, ankylosis, and erosion in a single ray; <bold>c</bold> enthesophytes at the plantar fascia and Achilles&#x2019; tendon insertions; and <bold>d</bold> syndesmophytes involving the cervical spine, with ankylosis of facet joints (arrow); <bold>e</bold> bilateral grade&#xA0;3 sacroiliitis; <bold>f</bold> paramarginal syndesmophyte bridging the fourth and fifth lumbar vertebrae; <bold>g</bold> bone marrow edema in the second and third lumbar vertebrae in a patient with severe psoriasis and new onset of back pain; <bold>h</bold> high-frequency (15&#xA0;MHz) grayscale ultrasound image shows synovitis of the metacarpophalangeal joint. Distention of the joint capsule is evident (arrows). The confluent red signals (box in the lower part of the image) with power Doppler ultrasonography indicate synovial hyperemia; and <bold>i</bold> high-frequency (15&#xA0;MHz) ultrasound image shows enthesitis. The confluent red signals with power Doppler ultrasonography represent hyperemia at the tendon near its insertion into the calcaneus. Normally, the tendon is poorly vascularized [<xref ref-type="bibr" rid="CR76">76</xref>]. <sup>b</sup>Unilateral acute sacroiliitis of the sacroiliac joints that can be seen on MRI. Coronal STIR sequence: high signal intensities on the right compatible with bone marrow edema (white arrows) and enthesitis (blue arrows)[<xref ref-type="bibr" rid="CR75">75</xref>]</p></caption><graphic xlink:href="40744_2021_365_Fig4_HTML" id="MO4"/></fig></p>
      <p id="Par15">US imaging is a useful tool that rheumatologists can use to help visualize inflammatory alterations in soft tissues, such as the synovium, tendons, and entheses, as well as superficial structural changes on the bone surface characteristic of PsA [<xref ref-type="bibr" rid="CR81">81</xref>, <xref ref-type="bibr" rid="CR82">82</xref>]. Synovitis in PsA is non-specific on US imaging but can pinpoint joint involvement, and a scoring system has been established by the Outcome Measures in Rheumatology (OMERACT) US Working Group to evaluate the degree of synovitis [<xref ref-type="bibr" rid="CR83">83</xref>]. US can support the early detection and prognosis of subclinical synovitis, and increased US detection of PsA has been reported compared with clinical examination, which can be used to prevent misdiagnosis [<xref ref-type="bibr" rid="CR84">84</xref>, <xref ref-type="bibr" rid="CR85">85</xref>]. US is commonly used to visualize enthesitis and has been reported to be superior to clinical examination for the detection of enthesitis in the lower limbs of patients with spondyloarthritis [<xref ref-type="bibr" rid="CR77">77</xref>, <xref ref-type="bibr" rid="CR86">86</xref>, <xref ref-type="bibr" rid="CR87">87</xref>]; the OMERACT US Task Force reached a consensus on the sonographic lesions that define spondyloarthritis-related enthesitis, and the GRAPPA US Working Group developed an US enthesitis score for PsA [<xref ref-type="bibr" rid="CR88">88</xref>]. Enthesitis in PsA is typified by five abnormalities: tendon thickening and hypoechogenicity, erosions, enthesophytes, calcifications, and abnormal blood flow detected by power Doppler signal at the entheses, all of which can be visualized via US imaging [<xref ref-type="bibr" rid="CR89">89</xref>]. Additionally, US imaging is the preferred method for imaging components of dactylitis to identify the characteristic flexor tenosynovitis and increased subcutaneous soft-tissue swelling, particularly in early disease [<xref ref-type="bibr" rid="CR90">90</xref>, <xref ref-type="bibr" rid="CR91">91</xref>].</p>
      <p id="Par16">The high sensitivity of MRI can be used for the early detection of active inflammatory responses that can be seen in early PsA, and the OMERACT MRI in Arthritis Working Group has developed definitions for pathologies commonly seen in PsA [<xref ref-type="bibr" rid="CR92">92</xref>]. The detailed MRI findings common in PsA include thickening of tendons and ligaments, joint effusions and inflammation, bone erosions, enthesophytes, and bone marrow edema [<xref ref-type="bibr" rid="CR93">93</xref>, <xref ref-type="bibr" rid="CR94">94</xref>]. Structural abnormalities often seen in patients with PsA, such as the localization of bone marrow edema in proximity to enthesitis, soft-tissue inflammation and tendon involvement [<xref ref-type="bibr" rid="CR95">95</xref>], and location of erosions, can be applied as distinguishing factors visible with MRI [<xref ref-type="bibr" rid="CR96">96</xref>, <xref ref-type="bibr" rid="CR97">97</xref>]. More specifically, APPs can note the location of bone marrow edema, which is near the entheses in PsA compared with the capsular attachments in RA, and areas of tenosynovitis are soft-tissue inflammation around the tendon sheath related to dactylitis as opposed to in the hands and wrists in RA [<xref ref-type="bibr" rid="CR95">95</xref>, <xref ref-type="bibr" rid="CR98">98</xref>]. However, small studies reported overlap of MRI findings in PsA and OA, such as bone marrow edema, synovitis, and periostitis, which can add to the challenge of a differential diagnosis [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR96">96</xref>, <xref ref-type="bibr" rid="CR99">99</xref>]. Additionally, for patients with disease that has progressed, the fat deposition and erosions characteristic of chronic inflammation can be visualized with MRI. Features of enthesitis and dactylitis can be visualized with MRI; however, detection in peripheral joints can be difficult because of the potential for low signal in areas with low water accumulation, such as bone attachments [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR100">100</xref>]. MRI is the preferred first-line modality for patients with suspected axial PsA who are younger and/or who have shorter disease duration [<xref ref-type="bibr" rid="CR101">101</xref>]. Active inflammation (i.e., synovitis and enthesitis) at the sacroiliac joints and bone marrow edema throughout the entire spine, for patients who may have more cervical involvement, can be evaluated via MRI; this is important as early detection prevents irreversible damage on plain film [<xref ref-type="bibr" rid="CR97">97</xref>, <xref ref-type="bibr" rid="CR101">101</xref>].</p>
      <p id="Par17">Computed tomography can illustrate the structural damage (i.e., bone erosion, sclerosis, joint space alterations) associated with axial involvement in PsA with high resolution; however, it is not recommended or widely used in routine clinical practice unless radiography is negative and the use of MRI is not possible.</p>
      <p id="Par18">Although each imaging modality has its advantages and limitations, imaging can be valuable for the differential diagnosis of PsA, the assessment of disease severity, monitoring of structural and inflammatory changes, and gauging treatment efficacy.</p>
    </sec>
    <sec id="Sec5">
      <title>Biomarkers That Can Facilitate Differentiation of PSA, RA, and OA</title>
      <p id="Par19">One challenge in the diagnosis of PsA is the lack of validated biomarkers detectable in the serum or synovial fluid that are unique to PsA; however, there are serologic, genetic, and inflammatory markers that can be screened to substantiate clinical findings.</p>
      <p id="Par20">Serologic analyses for rheumatoid factor (RF) and cyclic citrullinated peptide (CCP) can be used to facilitate the distinction between PsA and RA. Approximately 80% of patients with RA are RF positive and CCP positive, while nearly all patients with PsA are RF and/or CCP negative [<xref ref-type="bibr" rid="CR102">102</xref>]. However, it is important to not rule out PsA solely on the basis of CCP- and/or RF-negative status, as an estimated 13% of patients with PsA are RF positive [<xref ref-type="bibr" rid="CR33">33</xref>]. Additionally, C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) have been shown to be markers of inflammation in patients with RA and PsA. Both ESR and CRP were reported to significantly predict radiographic progression in RA [<xref ref-type="bibr" rid="CR8">8</xref>]. Patients with PsA, on average, have lower ESR and CRP levels than patients with RA, yet elevations of both have been significantly correlated with the number of swollen joints, structural damage, and abnormalities detected with US [<xref ref-type="bibr" rid="CR84">84</xref>, <xref ref-type="bibr" rid="CR103">103</xref>]. Elevated ESR and CRP levels that are attributed to PsA are considered markers of severe PsA by the American College of Rheumatology (ACR)/National Psoriasis Foundation, and tumor necrosis factor inhibitors (TNFis) and/or anti-interleukin-17 (IL-17) biologic disease-modifying antirheumatic drugs (bDMARDs) are recommended for earlier use in these patients [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR104">104</xref>, <xref ref-type="bibr" rid="CR105">105</xref>].</p>
      <p id="Par21">Genetic factors can also assist in differential diagnosis of PsA; HLA-B27, in particular, has been linked to the increased susceptibility to develop PsA among patients with psoriasis, which can also be affected by family history and/or race [<xref ref-type="bibr" rid="CR106">106</xref>, <xref ref-type="bibr" rid="CR107">107</xref>]. HLA-B27 has also been linked to development of enthesitis and symmetric sacroiliitis and is more common among patients with axial involvement than those without [<xref ref-type="bibr" rid="CR108">108</xref>, <xref ref-type="bibr" rid="CR109">109</xref>]. Among patients with RA who are RF and CCP positive, the presence of HLA-DRB1 alleles has been associated with disease severity and susceptibility to develop RA [<xref ref-type="bibr" rid="CR110">110</xref>]; this genetic factor is generally absent in patients with PsA but has been associated as a risk factor for inflammatory bowel disease and may indicate the presence of inflammatory bowel disease among patients diagnosed with PsA [<xref ref-type="bibr" rid="CR111">111</xref>]. While the presence of HLA-B27 or HLA-DRB1 alone would not constitute a definitive diagnosis, it can be used to substantiate a diagnosis along with clinical signs and symptoms.</p>
    </sec>
    <sec id="Sec6">
      <title>Treatment Recommendations and Guidelines for Management of PSA</title>
      <p id="Par22">Once a confirmed diagnosis of PsA is established, providers can utilize known inflammatory markers to facilitate determination of the optimal treatment strategy for patients. Inflammatory responses in arthritic diseases result in increased production of pro-inflammatory cytokines that act together to propagate chronic inflammation (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>). TNF&#x3B1; overexpression has been linked to the pathogenesis of PsA, RA, and OA [<xref ref-type="bibr" rid="CR112">112</xref>&#x2013;<xref ref-type="bibr" rid="CR114">114</xref>]. IL-17 is increased in the synovial fluid and psoriatic plaques of patients with PsA [<xref ref-type="bibr" rid="CR115">115</xref>&#x2013;<xref ref-type="bibr" rid="CR118">118</xref>]. Cytokines IL-12 and IL-23 also have established roles in the pathogenesis of PsA [<xref ref-type="bibr" rid="CR119">119</xref>&#x2013;<xref ref-type="bibr" rid="CR123">123</xref>]. Additionally, IL-6 dysregulation plays a key role in the development and progression of RA [<xref ref-type="bibr" rid="CR124">124</xref>&#x2013;<xref ref-type="bibr" rid="CR126">126</xref>] and has been associated with age-related inflammation and radiographic knee OA [<xref ref-type="bibr" rid="CR127">127</xref>], and increased IL-6 levels are seen in the synovium in PsA [<xref ref-type="bibr" rid="CR114">114</xref>, <xref ref-type="bibr" rid="CR128">128</xref>]. IL-1&#x3B2; plays a crucial role in the pathogenesis of OA [<xref ref-type="bibr" rid="CR129">129</xref>&#x2013;<xref ref-type="bibr" rid="CR131">131</xref>]. However, elevated levels of IL-1&#x3B2; are also frequently seen in PsA and RA [<xref ref-type="bibr" rid="CR132">132</xref>], so this dysregulation alone cannot be used to differentiate diagnosis. High numbers of activated T&#xA0;cells are found in the inflamed joints and skin of patients with PsA and have also been linked to the pathogenesis and progression of RA [<xref ref-type="bibr" rid="CR133">133</xref>&#x2013;<xref ref-type="bibr" rid="CR135">135</xref>]. Lastly, the role of the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is implicated in the pathogenesis of these diseases [<xref ref-type="bibr" rid="CR136">136</xref>&#x2013;<xref ref-type="bibr" rid="CR140">140</xref>]. Several cytokines that are upregulated in RA and/or PsA can promote increased cytokine release through several JAK/STAT pathways, potentiating further inflammatory responses that can propagate cycles of chronic inflammation [<xref ref-type="bibr" rid="CR137">137</xref>, <xref ref-type="bibr" rid="CR141">141</xref>]. Overlap in intracellular signaling cascades that are involved in the pathogenesis of each disease can add to the challenge of differentiating PsA from RA and OA; however, assessment of each of these markers may be part of a clinical examination to substantiate clinical presentation and could be used to determine optimal treatment plans.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Pro-inflammatory cytokines associated with disease pathogenesis of PsA, RA, and OA</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Cytokine</th><th align="left">Description</th><th align="left">Cell signaling regulation</th><th align="left">Targeted therapies</th></tr></thead><tbody><tr><td align="left">TNF&#x3B1; [<xref ref-type="bibr" rid="CR112">112</xref>&#x2013;<xref ref-type="bibr" rid="CR114">114</xref>]</td><td align="left">Inflammatory cytokine produced by Th1, Th22, Th17, NK, and dendritic cells, as well as macrophages and neutrophils</td><td align="left">Overexpression linked to pathogenesis of PsA, RA, and OA</td><td align="left">TNFis approved and recommended for PsA and RA include etanercept, infliximab, adalimumab, golimumab, and certolizumab pegol</td></tr><tr><td align="left">IL-17 [<xref ref-type="bibr" rid="CR115">115</xref>&#x2013;<xref ref-type="bibr" rid="CR118">118</xref>]</td><td align="left">Inflammatory cytokine produced by Th17, Th9, innate lymphoid, and mast cells, as well as neutrophils</td><td align="left"><p>Increased in the synovial fluid and psoriatic plaques of patients with PsA</p><p>Associated with pathogenesis of PsA but not established for RA or OA</p></td><td align="left">IL-17is approved and recommended for PsA include secukinumab and ixekizumab</td></tr><tr><td align="left">IL-12/23 and IL-23 [<xref ref-type="bibr" rid="CR119">119</xref>&#x2013;<xref ref-type="bibr" rid="CR123">123</xref>]</td><td align="left">Pro-inflammatory cytokines produced by dendritic cells and macrophages</td><td align="left"><p>IL-12 stimulates Th1 cells</p><p>IL-23 regulates Th17 cells at sites of enthesitis</p></td><td align="left">IL-12/23i and IL-23i approved and recommended for PsA are ustekinumab and guselkumab, respectively</td></tr><tr><td align="left">IL-6 [<xref ref-type="bibr" rid="CR124">124</xref>&#x2013;<xref ref-type="bibr" rid="CR128">128</xref>]</td><td align="left">Produced by dendritic cells, macrophages, and neutrophils</td><td align="left"><p>Elevated levels of IL-6 have been reported in the synovial fluid of patients with RA and PsA and the serum and plasma in patients with RA</p><p>Plays a role in RA progression via T and B&#xA0;cell activation, autoantibody and acute-phase protein production, and osteoclast and synoviocyte stimulation</p><p>Increased IL-6 levels have been associated with age-related inflammation and are predictive of radiographic knee OA</p></td><td align="left">IL-6 receptor antagonists approved and recommended for RA include tocilizumab and sarilumab</td></tr><tr><td align="left">IL-1&#x3B2; [<xref ref-type="bibr" rid="CR129">129</xref>&#x2013;<xref ref-type="bibr" rid="CR132">132</xref>]</td><td align="left">Produced by macrophages and neutrophils in the joint and synovial membrane</td><td align="left"><p>Shown to induce inflammation and catabolic effects of the articular cartilage and other aspects of joints leading to OA</p><p>Elevated levels are also seen in patients with PsA and RA</p></td><td align="left">IL-1 receptor antagonist approved for RA is anakinra</td></tr><tr><td align="left">T&#xA0;cells [<xref ref-type="bibr" rid="CR133">133</xref>&#x2013;<xref ref-type="bibr" rid="CR135">135</xref>]</td><td align="left">A type of white blood cell that is key to the function and regulation of the immune system to protect the body from infection</td><td align="left"><p>An increased number of activated T&#xA0;cells, including Th17 cells, are found in the inflamed joints and skin of patients with PsA</p><p>Aberrant regulation and function of Th and Treg cells have been linked to the pathogenesis and progression of RA</p></td><td align="left">A T&#xA0;cell co-stimulation modulator approved for RA and PsA is abatacept</td></tr><tr><td align="left">JAK/STAT [<xref ref-type="bibr" rid="CR136">136</xref>&#x2013;<xref ref-type="bibr" rid="CR139">139</xref>]</td><td align="left">Pro-inflammatory cytokines signal through and regulate the JAK/STAT pathways</td><td align="left">Several pro-inflammatory cytokines recruit and activate immune cells to sites of inflammation and increase cytokine regulation through JAK/STAT pathways</td><td align="left"><p>JAK inhibitor approved for PsA and RA is tofacitinib</p><p>JAK inhibitors approved for RA include baricitinib and upadacitinib</p></td></tr></tbody></table><table-wrap-foot><p><italic>IL-12/23i</italic> interleukin-12/23 inhibitor, <italic>IL-17i</italic> interleukin-17 inhibitor, <italic>IL-23i</italic> interleukin-23 inhibitor, <italic>JAK</italic> Janus kinase, <italic>NK</italic> natural killer, <italic>OA</italic> osteoarthritis, <italic>PsA</italic> psoriatic arthritis, <italic>RA</italic> rheumatoid arthritis, <italic>STAT</italic> signal transducer and activator of transcription, <italic>Th</italic> helper T&#xA0;cell, <italic>TNFi</italic> tumor necrosis factor inhibitor, <italic>Treg</italic> regulatory T&#xA0;cell</p></table-wrap-foot></table-wrap></p>
      <p id="Par23">Early treatment intervention of PsA has the potential to significantly impede disease progression and allow patients to maintain quality of life. Patients are often seen by several healthcare providers (e.g., primary care providers, dermatologists, orthopedists) along their journey to a definitive diagnosis. One study reported that among those surveyed, patients with PsA were most commonly treated by a general practitioner (79.8%), rheumatologist (66.5%), dermatologist (33.0%), and/or orthopedist (21.7%) and found that patients with increased time to diagnosis were significantly more likely to have initially sought care from general practitioners, orthopedists, and chiropractors [<xref ref-type="bibr" rid="CR22">22</xref>]. Upon appropriate identification of suspected PsA, a referral to a rheumatologist should follow, and a comprehensive referral is crucial to best assist in the diagnosis of PsA and choice of an appropriate treatment strategy. We recommend that patient history, imaging, laboratory tests, history of joint involvement, synovial fluid draining and findings (e.g., cell count, crystal deposits, and cultures), and the disease domains involved be included in a referral (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>). A study that included data for 405 newly diagnosed patients with PsA included in the Dutch south-west Early Psoriatic Arthritis cohort found diverse primary manifestations at time of diagnosis, with domain presentation ranges from 12.6% to 85% [<xref ref-type="bibr" rid="CR142">142</xref>]. Furthermore, in a study among 2617 patients with established PsA [mean (SD) disease duration of 8.5 (8.1) years] enrolled in a registry, domain presentation and comorbidities were varied; individual domain presentation ranged from 9.0% to 69.3%, and common comorbidities included uveitis (0.9%), Crohn&#x2019;s disease (1.0%), and ulcerative colitis (0.9%) (Fig.&#xA0;<xref rid="Fig5" ref-type="fig">5</xref>) [<xref ref-type="bibr" rid="CR143">143</xref>]. It is important for APPs to make note of the disease domain type and severity involved since it may impact treatment options and effectiveness.<fig id="Fig5"><label>Fig. 5</label><caption><p>Frequency of disease domains in patients with PsA. ASAS Assessment of SpondyloArthritis international Society, CBP chronic back pain, CD Crohn&#x2019;s disease, CVD cardiovascular disease, IBP inflammatory back pain, LDI Leeds Dactylitis Index, LEI Leeds Enthesitis Index, PA peripheral arthritis, PASI Psoriasis Area and Severity Index, PsA psoriatic arthritis, SPARCC Spondyloarthritis Research Consortium of Canada, SJC swollen joint count, TJC tender joint count, UC ulcerative colitis, VAS visual analog scale. <sup>a</sup>Disease domains were defined as follows: (1) enthesitis: patients with LEI&#x2009;&gt;&#x2009;0; (2) dactylitis: determined by LDI&#x2009;&gt;&#x2009;0; (3) PA: disease subtype was determined at diagnosis by rheumatologist and defined by primary presentation as monoarthritis (1&#xA0;joint), oligoarthritis (2&#x2013;4&#xA0;joints), and polyarthritis (&#x2265;&#x2009;5&#xA0;joints); (4) axial involvement: patients were classified as having CBP if they reported chronic complaints of back pain for a duration of longer than 3&#xA0;months at present or in the past 12&#xA0;months and with onset&#x2009;&lt;&#x2009;45&#xA0;years of age. Of these patients, fulfillment of the ASAS classification criteria for IBP was determined; (5) psoriasis: patients with PASI&#x2009;&gt;&#x2009;1 [<xref ref-type="bibr" rid="CR142">142</xref>]. <sup>b</sup>Disease domains were defined as follows: (1) enthesitis: patients with SPARCC&#x2009;&gt;&#x2009;1; (2) dactylitis: patients with peripheral dactylitis&#x2009;&gt;&#x2009;1; (3) PA: patients with TJC and/or SJC&#x2009;&gt;&#x2009;0; (4) nail psoriasis: patients with global nail psoriasis severity VAS&#x2009;&gt;&#x2009;0; (5) axial disease: patients with physician-reported presence of spinal involvement at time of registry enrollment, based on clinical judgment of features thought to be representative of active inflammatory spondylitis and/or radiographs or magnetic resonance imaging (MRI) showing sacroiliitis such as sacroiliitis grade&#x2009;&gt;&#x2009;2 bilaterally or grades&#xA0;3&#x2013;4 unilaterally by x-ray, active (acute) inflammation on MRI highly suggestive of sacroiliitis associated with SpA, definite radiographic sacroiliitis according to modified New York criteria, and other evidence of sacroiliitis on imaging; and (6) skin disease: patients with&#x2009;&gt;&#x2009;0% body surface area affected by psoriasis</p></caption><graphic xlink:href="40744_2021_365_Fig5_HTML" id="MO5"/></fig></p>
      <p id="Par24">The care and management of PsA relies primarily on pharmacological measures, and the appropriate choice is vital to optimize treatment response. There is overlap in approved treatment options for PsA, RA, and OA (Table&#xA0;<xref rid="Tab2" ref-type="table">2</xref>) [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR105">105</xref>, <xref ref-type="bibr" rid="CR144">144</xref>&#x2013;<xref ref-type="bibr" rid="CR149">149</xref>]; therefore, a definitive diagnosis of PsA is paramount for the appropriate choice to optimize therapeutic response. Different classes of DMARDs are indicated for PsA and RA, including conventional synthetic (csDMARDs), biologic (bDMARDs), and targeted synthetic (tsDMARDs) [<xref ref-type="bibr" rid="CR105">105</xref>, <xref ref-type="bibr" rid="CR146">146</xref>]; however, none of these are approved for OA. csDMARDs, along with nonsteroidal anti-inflammatory drugs (NSAIDs) and glucocorticoids, are widely used as initial treatment for the signs and symptoms of PsA and RA, and NSAIDs are used for patients with OA. The overlap of approved csDMARDs for PsA and RA include methotrexate and leflunomide, while there are a number of other csDMARDs indicated for RA but not PsA [<xref ref-type="bibr" rid="CR9">9</xref>]. The majority of bDMARDs have been widely recognized for their ability to effectively improve signs and symptoms and inhibit the structural progression seen with PsA and RA, although targeting IL-12/23 and IL-23 has not been reported to inhibit structural progression; there are inconclusive and limited data on the use of bDMARDs in OA [<xref ref-type="bibr" rid="CR105">105</xref>, <xref ref-type="bibr" rid="CR150">150</xref>]. TNFis are approved for active PsA and RA and have been widely established as an effective bDMARD for these patients. More selective novel bDMARDs have been developed with different mechanisms of action linked to PsA and RA, including those that target IL-17 [<xref ref-type="bibr" rid="CR151">151</xref>, <xref ref-type="bibr" rid="CR152">152</xref>], IL-12/23 [<xref ref-type="bibr" rid="CR153">153</xref>&#x2013;<xref ref-type="bibr" rid="CR156">156</xref>], and IL-23 [<xref ref-type="bibr" rid="CR157">157</xref>, <xref ref-type="bibr" rid="CR158">158</xref>] in PsA; IL-1 [<xref ref-type="bibr" rid="CR159">159</xref>, <xref ref-type="bibr" rid="CR160">160</xref>], CD20 [<xref ref-type="bibr" rid="CR161">161</xref>], and IL-6 [<xref ref-type="bibr" rid="CR162">162</xref>] in RA; and T&#xA0;cell modulation in both RA and PsA [<xref ref-type="bibr" rid="CR163">163</xref>, <xref ref-type="bibr" rid="CR164">164</xref>]. More recently, tsDMARDs that specifically target JAK/STAT and phosphodiesterase&#xA0;4 (PDE4) have been approved in PsA and RA owing to the growing evidence of the dysregulation of these pathways in both diseases, although more tsDMARDs are approved for RA than PsA [<xref ref-type="bibr" rid="CR165">165</xref>&#x2013;<xref ref-type="bibr" rid="CR167">167</xref>]. Given the overlap in treatment options for PsA, RA, and OA, a differential diagnosis is imperative prior to treatment initiation as variations in inflammatory responses and patient demographics may arise from different mechanisms of action, which should be considered for the development of an appropriate treatment plan.<table-wrap id="Tab2"><label>Table 2</label><caption><p>FDA-approved therapies for PsA, RA, and OA</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Class</th><th align="left">PsA [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR105">105</xref>, <xref ref-type="bibr" rid="CR144">144</xref>]</th><th align="left">RA [<xref ref-type="bibr" rid="CR145">145</xref>, <xref ref-type="bibr" rid="CR146">146</xref>]</th><th align="left">OA [<xref ref-type="bibr" rid="CR147">147</xref>&#x2013;<xref ref-type="bibr" rid="CR149">149</xref>]</th></tr></thead><tbody><tr><td align="left">csDMARDs</td><td align="left">MTX, leflunomide, sulfasalazine, cyclosporine</td><td align="left">MTX, leflunomide, sulfasalazine, hydroxychloroquine, cyclosporine</td><td align="left"/></tr><tr><td align="left">bDMARDs</td><td align="left"><p>TNFis: etanercept, infliximab, adalimumab, golimumab, certolizumab pegol</p><p>IL-17 inhibitors: secukinumab, ixekizumab</p><p>IL-12/23 inhibitor: ustekinumab</p><p>IL-23 inhibitor: guselkumab</p><p>T-cell activation inhibitor: abatacept</p></td><td align="left"><p>TNFis: etanercept, infliximab, adalimumab, golimumab, certolizumab pegol</p><p>IL-6 receptor antagonists: tocilizumab, sarilumab</p><p>IL-1 receptor antagonist: anakinra</p><p>T-cell activation inhibitor: abatacept</p><p>CD20 inhibitor: rituximab</p></td><td align="left"/></tr><tr><td align="left">tsDMARDs</td><td align="left"><p>PDE4 inhibitor: apremilast</p><p>JAK inhibitor: tofacitinib</p></td><td align="left">JAK inhibitors: tofacitinib, baricitinib, upadacitinib</td><td align="left"/></tr><tr><td align="left">Other</td><td align="left"><p>Corticosteroid injections</p><p>NSAIDs</p></td><td align="left"><p>Corticosteroid injections</p><p>NSAIDs</p></td><td align="left"><p>Corticosteroid injections</p><p>NSAIDs</p><p>Opioids: tramadol</p><p>Non-pharmacological interventions:</p><p>&#xA0;&#xA0;Exercise</p><p>&#xA0;&#xA0;Weight management</p><p>&#xA0;&#xA0;Strength training</p><p>&#xA0;&#xA0;Self-management and education</p></td></tr></tbody></table><table-wrap-foot><p><italic>bDMARD</italic> biologic DMARD, <italic>csDMARD</italic> conventional synthetic DMARD, <italic>DMARD</italic> disease-modifying antirheumatic drug, <italic>IL</italic> interleukin, <italic>JAK</italic> Janus kinase, <italic>MTX</italic> methotrexate, <italic>NSAID</italic> nonsteroidal anti-inflammatory drug, <italic>OA</italic> osteoarthritis, <italic>PsA</italic> psoriatic arthritis, <italic>PDE4</italic> phosphodiesterase&#xA0;4, <italic>RA</italic> rheumatoid arthritis, <italic>TNFi</italic> tumor necrosis factor inhibitor, <italic>tsDMARD</italic> targeted synthetic DMARD</p></table-wrap-foot></table-wrap></p>
      <p id="Par25">Guidelines and treatment recommendations present healthcare providers with the best evidence available for circumstances commonly seen in patients to allow practitioners to deliver optimal care. Recommendations and guidelines for the treatment of PsA have been developed by the European League Against Rheumatism, GRAPPA, and ACR/National Psoriasis Foundation, which broadly propose an escalation-type approach to therapy and can be managed and initiated by rheumatology providers following an appropriate referral [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR105">105</xref>, <xref ref-type="bibr" rid="CR144">144</xref>]. Similar recommendations are also available for RA [<xref ref-type="bibr" rid="CR146">146</xref>] and OA [<xref ref-type="bibr" rid="CR147">147</xref>].</p>
      <p id="Par26">Approved treatment strategies differ because of the differences in pathogenesis, clinical presentation, and response to therapy among patients; therefore, an accurate disease diagnosis is imperative as it can have crucial implications for therapeutic response (Table&#xA0;<xref rid="Tab2" ref-type="table">2</xref>). Treatments that are less specific, such as NSAIDs and corticosteroid injections, have been shown to be effective for treatment of the symptoms of PsA, RA [<xref ref-type="bibr" rid="CR145">145</xref>], and OA [<xref ref-type="bibr" rid="CR148">148</xref>, <xref ref-type="bibr" rid="CR149">149</xref>], and these agents could be used for initial disease management before a differential diagnosis and prognosis can be determined.</p>
      <p id="Par27">Once a diagnosis is established, it is imperative to consider which PsA disease domains are involved to select the appropriate treatment for optimal effectiveness (Table&#xA0;<xref rid="Tab3" ref-type="table">3</xref>) [<xref ref-type="bibr" rid="CR105">105</xref>]. Data on the efficacy of csDMARDs, especially methotrexate, in PsA are varied; historically, methotrexate has not been shown to be effective for improving measures of synovitis, including joint counts, and ESR and CRP levels or for delaying radiographic progression but is effective for skin involvement seen with the disease. More recently, methotrexate has been shown to improve ACR20 responses among treatment-naive patients with PsA in randomized controlled trials [<xref ref-type="bibr" rid="CR168">168</xref>&#x2013;<xref ref-type="bibr" rid="CR171">171</xref>]. Conversely, the efficacy of methotrexate in patients with RA is well established and is the most frequently used csDMARD for first-line therapy [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR145">145</xref>]. The use of csDMARDs in OA is less understood and the data are not robust enough to encourage incorporation of treatment into clinical practice; however, there is some evidence that methotrexate may be effective for pain reduction seen in OA of the knee [<xref ref-type="bibr" rid="CR172">172</xref>, <xref ref-type="bibr" rid="CR173">173</xref>].<table-wrap id="Tab3"><label>Table 3</label><caption><p>Recommended treatments for PsA by disease domain involvement [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR105">105</xref>, <xref ref-type="bibr" rid="CR144">144</xref>]</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Disease domain</th><th align="left">Treatment recommendation<sup>a</sup></th></tr></thead><tbody><tr><td align="left">Enthesitis<sup>b</sup></td><td align="left"><p>First line: NSAIDs,</p><p>Inadequate response to NSAIDs: csDMARDs, TNFis, IL-12/23i, IL-17is, JAKi</p></td></tr><tr><td align="left">Dactylitis<sup>b</sup></td><td align="left"><p>First line: csDMARDs</p><p>Inadequate response to csDMARDs/TNFis: switch TNFis, IL-17is, IL-12/23i</p></td></tr><tr><td align="left">Peripheral arthritis<sup>b</sup></td><td align="left"><p>First line: csDMARDs, TNFis, NSAIDs,</p><p>Inadequate response to prior DMARDs: IL-12/23i, IL-17is, JAKi</p><p>Inadequate response to prior DMARDs with skin involvement: IL-17is, IL-12/23i</p></td></tr><tr><td align="left">Nail psoriasis</td><td align="left"><p>First line: TNFis, IL-12/23i, IL-17i</p><p>Inadequate response to prior biologics: switch biologic or PDE4i</p></td></tr><tr><td align="left">Axial disease</td><td align="left"><p>First line: NSAIDs</p><p>Inadequate response to prior NSAIDs: TNFis</p><p>Inadequate response to prior NSAIDs with skin involvements: IL-17is</p></td></tr><tr><td align="left">Psoriatic skin disease</td><td align="left"><p>First line: topical treatments, csDMARDs, particularly MTX</p><p>Inadequate response to csDMARDs: IL-17is, IL-12/23i, TNFis, PDE4i<sup>c</sup></p></td></tr></tbody></table><table-wrap-foot><p><italic>bDMARD</italic> biologic DMARD, <italic>CS</italic> corticosteroids, <italic>csDMARD</italic> conventional synthetic DMARD, <italic>DMARD</italic> disease-modifying antirheumatic drug, <italic>IL-12/23i</italic> interleukin-12/23 inhibitor, <italic>IL-17i</italic> interleukin-17 inhibitor, <italic>JAKi</italic> Janus kinase inhibitor, <italic>MTX</italic> methotrexate, <italic>NSAID</italic> nonsteroidal anti-inflammatory drug, <italic>PDE4i</italic> phosphodiesterase&#xA0;4&#xA0;inhibitor, <italic>PsA</italic> psoriatic arthritis, <italic>TNFi</italic> tumor necrosis factor inhibitor</p><p><sup>a</sup>Treatment recommendations do not include evidence for IL-23 inhibitors, as none were approved for PsA at the time of their publication</p><p><sup>b</sup>CS injections can be considered on an individual basis for peripheral arthritis, enthesitis, and dactylitis because of the potential for serious side effects and inadequate available evidence for efficacy</p><p><sup>c</sup>In patients with mild disease</p></table-wrap-foot></table-wrap></p>
      <p id="Par28">Therapeutic agents that target upstream factors, such as TNFis, are effective and recommended for the treatment of both RA and PsA [<xref ref-type="bibr" rid="CR105">105</xref>, <xref ref-type="bibr" rid="CR145">145</xref>]. TNFis are broadly effective; they are recommended to treat PsA-related enthesitis, dactylitis, and nail disease and are effective for PsA disease that is predominately axial. TNFis may be the preferred first and second bDMARDs for patients with concurrent uveitis [<xref ref-type="bibr" rid="CR105">105</xref>, <xref ref-type="bibr" rid="CR144">144</xref>]. However, increasing evidence has shown that newer bDMARDs that block IL-17, IL-12/23, or IL-23 have increased efficacy and better long-term safety profiles compared with TNFis in PsA, particularly for skin and nail disease, with fewer adverse events [<xref ref-type="bibr" rid="CR174">174</xref>&#x2013;<xref ref-type="bibr" rid="CR177">177</xref>]; these biologics are now recommended alongside TNFis for first-line therapy. IL-17 inhibitors may be preferred as first-line therapy for PsA with predominant skin involvement [<xref ref-type="bibr" rid="CR176">176</xref>]. Additionally, IL-12/23 inhibitors do not show sufficient efficacy for axial involvement compared with TNFis, so they are not recommended when axial involvement is present [<xref ref-type="bibr" rid="CR178">178</xref>]. These bDMARDs have shown superior efficacy for PsA treatment; however, the efficacy for RA is varied, and it has not been studied in OA [<xref ref-type="bibr" rid="CR179">179</xref>, <xref ref-type="bibr" rid="CR180">180</xref>]. Similarly, more selective bDMARDs have been increasingly shown to be more effective for the treatment of RA [<xref ref-type="bibr" rid="CR146">146</xref>, <xref ref-type="bibr" rid="CR181">181</xref>]. Patients with RA will benefit from the use of bDMARDs that target IL-6 and CD20, especially after inadequate response to TNFis, while their efficacy in patients with PsA is not established. Further, inhibition of T&#xA0;cell activation with abatacept treatment can be used in patients with RA, as well as those with PsA, who fail to respond to other bDMARDs.</p>
      <p id="Par29">For patients with an inadequate response to TNFis and other bDMARDs, tsDMARDs are increasingly recommended for patients with PsA (oral small molecules targeting JAK or PDE4) and RA (targeting JAK only). The efficacy of JAK inhibition in PsA has been established for patients with inadequate response or intolerance to csDMARDs and has been reported to significantly improve physical function, psoriasis, enthesitis, and dactylitis related to PsA [<xref ref-type="bibr" rid="CR165">165</xref>, <xref ref-type="bibr" rid="CR182">182</xref>]. Similarly, inhibiting PDE4 has been reported to significantly improve signs and symptoms of PsA and patient-reported outcome measures with sustained response up to 5&#xA0;years regardless of prior bDMARD experience; however, inhibition of radiographic progression is not established with PDE4 inhibition [<xref ref-type="bibr" rid="CR183">183</xref>, <xref ref-type="bibr" rid="CR184">184</xref>]. tsDMARDs effectively improve clinical manifestations, disease activity, and patient-related outcome measures of RA compared with csDMARDs, although greater improvements are achieved when administered in combination with csDMARDs [<xref ref-type="bibr" rid="CR166">166</xref>, <xref ref-type="bibr" rid="CR181">181</xref>]. While efficacy of tsDMARDs has been recognized for both diseases, it is still important to differentiate PsA from RA for the consideration of tsDMARD treatment since some agents have not been thoroughly studied in PsA and may not be as effective as in RA. Although PsA, RA, and OA have various overlapping clinical manifestations, variations in underlying pathogenesis and response to therapy translate into significantly varying clinical outcomes.</p>
    </sec>
    <sec id="Sec7" sec-type="conclusion">
      <title>Summary</title>
      <p id="Par30">PsA is a complex disease characterized by inflammation of multiple clinical domains, including peripheral joints, skin and nails, axial joints, entheses, eyes, and digits. There are many systemic treatment options available that are dictated by disease severity and that have demonstrated effective control of joint damage as assessed by radiographic progression. Early assessment, diagnosis, and treat-to-target strategies are key to the management of patients with PsA to facilitate the administration of appropriate therapy in a timely manner. Skin manifestations of psoriasis, which often develop before arthritic symptoms, place the responsibility on the dermatologist or primary care provider to screen for arthritis and enhance early diagnosis. Collaboration and coordinated care are key among primary care providers and subspecialists to ensure positive outcomes for patients, controlling symptoms and disease activity, maintaining functional ability, and improving patient quality of life.</p>
    </sec>
  </body>
  <back>
    <ack>
      <sec id="FPar01">
        <title>Funding</title>
        <p id="Par31">Support for third-party writing assistance for this manuscript and the Rapid Service Fee was provided by Novartis.</p>
      </sec>
      <sec id="FPar2">
        <title>Medical Writing and Editorial Assistance</title>
        <p id="Par32">The authors thank Linda Grinnell-Merrick, NP, of Novartis Pharmaceuticals Corporation, East Hanover, NJ for providing medical expertise and content development, and Charli Dominguez, PhD, of Health Interactions, Inc, Chicago, IL, for providing medical writing support/editorial support; funding was provided by Novartis Pharmaceuticals Corporation, East Hanover, NJ, in accordance with Good Publication Practice (GPP3) guidelines (<ext-link ext-link-type="uri" xlink:href="http://www.ismpp.org/gpp3">http://www.ismpp.org/gpp3</ext-link>). Authors had full control of the content and made the final decision on all aspects of this publication.</p>
      </sec>
      <sec id="FPar3">
        <title>Authorship</title>
        <p id="Par33">All named authors meet the International Committee of Medical Journal Editors criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.</p>
      </sec>
      <sec id="FPar4">
        <title>Authorship Contributions</title>
        <p id="Par34">William Saalfeld, Amanda M. Mixon, Jonna Zelie, and Eileen J. Lydon were responsible for the conceptualization and design of the review, critically reviewing and revising all drafts of the review, and approving the final version of the manuscript.</p>
      </sec>
      <sec id="FPar5">
        <title>Disclosures</title>
        <p id="Par35">W. Saalfeld received speaker and/or honoraria from Amgen (previously Celgene), Novartis, Pfizer, and Regeneron. A. M. Mixon received speaker fees/honoraria from AbbVie, Lilly, and Novartis, and has participated in an advisory board for Novartis. E. J. Lydon received speaker fees/honoraria from AbbVie and Sanofi. J. Zelie has nothing to disclose.</p>
      </sec>
      <sec id="FPar6">
        <title>Compliance with Ethics Guidelines</title>
        <p id="Par36">This review is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors; therefore, ethical approval was not required.</p>
      </sec>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mease</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Gladman</surname>
              <given-names>DD</given-names>
            </name>
            <name>
              <surname>Papp</surname>
              <given-names>KA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics</article-title>
          <source>J Am Acad Dermatol</source>
          <year>2013</year>
          <volume>69</volume>
          <issue>5</issue>
          <fpage>729</fpage>
          <lpage>735</lpage>
          <pub-id pub-id-type="pmid">23981683</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ogdie</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>The epidemiology of psoriatic arthritis</article-title>
          <source>Rheum Dis Clin North Am</source>
          <year>2015</year>
          <volume>41</volume>
          <issue>4</issue>
          <fpage>545</fpage>
          <lpage>568</lpage>
          <pub-id pub-id-type="pmid">26476218</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Singh</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Guyatt</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Ogdie</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Special article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the treatment of psoriatic arthritis</article-title>
          <source>Arthritis Care Res (Hoboken)</source>
          <year>2019</year>
          <volume>71</volume>
          <issue>1</issue>
          <fpage>2</fpage>
          <lpage>29</lpage>
          <pub-id pub-id-type="pmid">30499259</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gladman</surname>
              <given-names>DD</given-names>
            </name>
            <name>
              <surname>Mease</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Healy</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Outcome measures in psoriatic arthritis</article-title>
          <source>J Rheumatol</source>
          <year>2007</year>
          <volume>34</volume>
          <issue>5</issue>
          <fpage>1159</fpage>
          <lpage>1166</lpage>
          <pub-id pub-id-type="pmid">17477479</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Orbai</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>de Wit</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mease</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials</article-title>
          <source>Ann Rheum Dis</source>
          <year>2017</year>
          <volume>76</volume>
          <issue>4</issue>
          <fpage>673</fpage>
          <lpage>680</lpage>
          <pub-id pub-id-type="pmid">27613807</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gladman</surname>
              <given-names>DD</given-names>
            </name>
          </person-group>
          <article-title>Clinical features and diagnostic considerations in psoriatic arthritis</article-title>
          <source>Rheum Dis Clin North Am</source>
          <year>2015</year>
          <volume>41</volume>
          <issue>4</issue>
          <fpage>569</fpage>
          <lpage>579</lpage>
          <pub-id pub-id-type="pmid">26476219</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McGonagle</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Hermann</surname>
              <given-names>KG</given-names>
            </name>
            <name>
              <surname>Tan</surname>
              <given-names>AL</given-names>
            </name>
          </person-group>
          <article-title>Differentiation between osteoarthritis and psoriatic arthritis: implications for pathogenesis and treatment in the biologic therapy era</article-title>
          <source>Rheumatology (Oxford)</source>
          <year>2015</year>
          <volume>54</volume>
          <issue>1</issue>
          <fpage>29</fpage>
          <lpage>38</lpage>
          <pub-id pub-id-type="pmid">25231177</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <mixed-citation publication-type="other">Merola JF, Espinoza LR, Fleischmann R. Distinguishing rheumatoid arthritis from psoriatic arthritis. RMD Open. 2018;4(2):e000656.</mixed-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Coates</surname>
              <given-names>LC</given-names>
            </name>
            <name>
              <surname>FitzGerald</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Helliwell</surname>
              <given-names>PS</given-names>
            </name>
            <name>
              <surname>Paul</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Psoriasis, psoriatic arthritis, and rheumatoid arthritis: is all inflammation the same?</article-title>
          <source>Semin Arthritis Rheum</source>
          <year>2016</year>
          <volume>46</volume>
          <issue>3</issue>
          <fpage>291</fpage>
          <lpage>304</lpage>
          <pub-id pub-id-type="pmid">27388027</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Smolen</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Aletaha</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>McInnes</surname>
              <given-names>IB</given-names>
            </name>
          </person-group>
          <article-title>Rheumatoid arthritis</article-title>
          <source>Lancet</source>
          <year>2016</year>
          <volume>388</volume>
          <issue>10055</issue>
          <fpage>2023</fpage>
          <lpage>2038</lpage>
          <pub-id pub-id-type="pmid">27156434</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Scott</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Wolfe</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Huizinga</surname>
              <given-names>TW</given-names>
            </name>
          </person-group>
          <article-title>Rheumatoid arthritis</article-title>
          <source>Lancet</source>
          <year>2010</year>
          <volume>376</volume>
          <issue>9746</issue>
          <fpage>1094</fpage>
          <lpage>1108</lpage>
          <pub-id pub-id-type="pmid">20870100</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Safiri</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kolahi</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Hoy</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Global, regional and national burden of rheumatoid arthritis 1990&#x2013;2017: a systematic analysis of the Global Burden of Disease study 2017</article-title>
          <source>Ann Rheum Dis</source>
          <year>2019</year>
          <volume>78</volume>
          <issue>11</issue>
          <fpage>1463</fpage>
          <lpage>1471</lpage>
          <pub-id pub-id-type="pmid">31511227</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Glyn-Jones</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Palmer</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Agricola</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Osteoarthritis</article-title>
          <source>Lancet</source>
          <year>2015</year>
          <volume>386</volume>
          <issue>9991</issue>
          <fpage>376</fpage>
          <lpage>387</lpage>
          <pub-id pub-id-type="pmid">25748615</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Punzi</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Ramonda</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Sfriso</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Erosive osteoarthritis</article-title>
          <source>Best Pract Res Clin Rheumatol</source>
          <year>2004</year>
          <volume>18</volume>
          <issue>5</issue>
          <fpage>739</fpage>
          <lpage>758</lpage>
          <pub-id pub-id-type="pmid">15454130</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Anandarajah</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Erosive osteoarthritis</article-title>
          <source>Discov Med</source>
          <year>2010</year>
          <volume>9</volume>
          <issue>48</issue>
          <fpage>468</fpage>
          <lpage>477</lpage>
          <pub-id pub-id-type="pmid">20515616</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gazeley</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Yeturi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Patel</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Rosenthal</surname>
              <given-names>AK</given-names>
            </name>
          </person-group>
          <article-title>Erosive osteoarthritis: a systematic analysis of definitions used in the literature</article-title>
          <source>Semin Arthritis Rheum</source>
          <year>2017</year>
          <volume>46</volume>
          <issue>4</issue>
          <fpage>395</fpage>
          <lpage>403</lpage>
          <pub-id pub-id-type="pmid">27692966</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Neogi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Epidemiology of osteoarthritis</article-title>
          <source>Rheum Dis Clin North Am</source>
          <year>2013</year>
          <volume>39</volume>
          <issue>1</issue>
          <fpage>1</fpage>
          <lpage>19</lpage>
          <pub-id pub-id-type="pmid">23312408</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oliveria</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Felson</surname>
              <given-names>DT</given-names>
            </name>
            <name>
              <surname>Reed</surname>
              <given-names>JI</given-names>
            </name>
            <name>
              <surname>Cirillo</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Walker</surname>
              <given-names>AM</given-names>
            </name>
          </person-group>
          <article-title>Incidence of symptomatic hand, hip, and knee osteoarthritis among patients in a health maintenance organization</article-title>
          <source>Arthritis Rheum</source>
          <year>1995</year>
          <volume>38</volume>
          <issue>8</issue>
          <fpage>1134</fpage>
          <lpage>1141</lpage>
          <pub-id pub-id-type="pmid">7639811</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <mixed-citation publication-type="other">Global Burden of Disease Study Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990&#x2013;2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386(9995):743&#x2013;800.</mixed-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Haroon</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gallagher</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>FitzGerald</surname>
              <given-names>O</given-names>
            </name>
          </person-group>
          <article-title>Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis</article-title>
          <source>Ann Rheum Dis</source>
          <year>2015</year>
          <volume>74</volume>
          <issue>6</issue>
          <fpage>1045</fpage>
          <lpage>1050</lpage>
          <pub-id pub-id-type="pmid">24525911</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McHugh</surname>
              <given-names>NJ</given-names>
            </name>
            <name>
              <surname>Balachrishnan</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>SM</given-names>
            </name>
          </person-group>
          <article-title>Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study</article-title>
          <source>Rheumatology (Oxford)</source>
          <year>2003</year>
          <volume>42</volume>
          <issue>6</issue>
          <fpage>778</fpage>
          <lpage>783</lpage>
          <pub-id pub-id-type="pmid">12730539</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ogdie</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Nowell</surname>
              <given-names>WB</given-names>
            </name>
            <name>
              <surname>Applegate</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Patient perspectives on the pathway to psoriatic arthritis diagnosis: results from a web-based survey of patients in the United States</article-title>
          <source>BMC Rheumatol</source>
          <year>2020</year>
          <volume>4</volume>
          <fpage>2</fpage>
          <pub-id pub-id-type="pmid">31938764</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Taylor</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Gladman</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Helliwell</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Classification criteria for psoriatic arthritis: development of new criteria from a large international study</article-title>
          <source>Arthritis Rheum</source>
          <year>2006</year>
          <volume>54</volume>
          <issue>8</issue>
          <fpage>2665</fpage>
          <lpage>2673</lpage>
          <pub-id pub-id-type="pmid">16871531</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gottlieb</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Merola</surname>
              <given-names>JF</given-names>
            </name>
          </person-group>
          <article-title>Psoriatic arthritis for dermatologists</article-title>
          <source>J Dermatolog Treat</source>
          <year>2020</year>
          <volume>31</volume>
          <issue>7</issue>
          <fpage>662</fpage>
          <lpage>679</lpage>
          <pub-id pub-id-type="pmid">31014154</pub-id>
        </element-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mease</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Armstrong</surname>
              <given-names>AW</given-names>
            </name>
          </person-group>
          <article-title>Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis</article-title>
          <source>Drugs</source>
          <year>2014</year>
          <volume>74</volume>
          <issue>4</issue>
          <fpage>423</fpage>
          <lpage>441</lpage>
          <pub-id pub-id-type="pmid">24566842</pub-id>
        </element-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mease</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Karki</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Palmer</surname>
              <given-names>JB</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Clinical and patient-reported outcomes in patients with psoriatic arthritis (PsA) by body surface area affected by psoriasis: results from the Corrona PsA/Spondyloarthritis registry</article-title>
          <source>J Rheumatol</source>
          <year>2017</year>
          <volume>44</volume>
          <issue>8</issue>
          <fpage>1151</fpage>
          <lpage>1158</lpage>
          <pub-id pub-id-type="pmid">28620063</pub-id>
        </element-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schett</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Lories</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>D'Agostino</surname>
              <given-names>MA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Enthesitis: from pathophysiology to treatment</article-title>
          <source>Nat Rev Rheumatol</source>
          <year>2017</year>
          <volume>13</volume>
          <issue>12</issue>
          <fpage>731</fpage>
          <lpage>741</lpage>
          <pub-id pub-id-type="pmid">29158573</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gladman</surname>
              <given-names>DD</given-names>
            </name>
            <name>
              <surname>Ziouzina</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Thavaneswaran</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Chandran</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>Dactylitis in psoriatic arthritis: prevalence and response to therapy in the biologic era</article-title>
          <source>J Rheumatol</source>
          <year>2013</year>
          <volume>40</volume>
          <issue>8</issue>
          <fpage>1357</fpage>
          <lpage>1359</lpage>
          <pub-id pub-id-type="pmid">23818708</pub-id>
        </element-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brockbank</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Stein</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Schentag</surname>
              <given-names>CT</given-names>
            </name>
            <name>
              <surname>Gladman</surname>
              <given-names>DD</given-names>
            </name>
          </person-group>
          <article-title>Dactylitis in psoriatic arthritis: a marker for disease severity?</article-title>
          <source>Ann Rheum Dis</source>
          <year>2005</year>
          <volume>64</volume>
          <issue>2</issue>
          <fpage>188</fpage>
          <lpage>190</lpage>
          <pub-id pub-id-type="pmid">15271771</pub-id>
        </element-citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Geijer</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lindqvist</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Husmark</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The Swedish Early Psoriatic Arthritis Registry 5-year followup: substantial radiographic progression mainly in men with high disease activity and development of dactylitis</article-title>
          <source>J Rheumatol</source>
          <year>2015</year>
          <volume>42</volume>
          <issue>11</issue>
          <fpage>2110</fpage>
          <lpage>2117</lpage>
          <pub-id pub-id-type="pmid">26472410</pub-id>
        </element-citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kaeley</surname>
              <given-names>GS</given-names>
            </name>
            <name>
              <surname>Eder</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Aydin</surname>
              <given-names>SZ</given-names>
            </name>
            <name>
              <surname>Gutierrez</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bakewell</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Dactylitis: a hallmark of psoriatic arthritis</article-title>
          <source>Semin Arthritis Rheum</source>
          <year>2018</year>
          <volume>48</volume>
          <issue>2</issue>
          <fpage>263</fpage>
          <lpage>273</lpage>
          <pub-id pub-id-type="pmid">29573849</pub-id>
        </element-citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chang</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Gottlieb</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Lizzul</surname>
              <given-names>PF</given-names>
            </name>
          </person-group>
          <article-title>Management of psoriatic arthritis from the view of the dermatologist</article-title>
          <source>Nat Rev Rheumatol</source>
          <year>2011</year>
          <volume>7</volume>
          <issue>10</issue>
          <fpage>588</fpage>
          <lpage>598</lpage>
          <pub-id pub-id-type="pmid">21912431</pub-id>
        </element-citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <mixed-citation publication-type="other">Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64 Suppl 2:ii14&#x2013;17.</mixed-citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Reich</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kruger</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Mossner</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Augustin</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis</article-title>
          <source>Br J Dermatol</source>
          <year>2009</year>
          <volume>160</volume>
          <issue>5</issue>
          <fpage>1040</fpage>
          <lpage>1047</lpage>
          <pub-id pub-id-type="pmid">19210498</pub-id>
        </element-citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wilson</surname>
              <given-names>FC</given-names>
            </name>
            <name>
              <surname>Icen</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Crowson</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>McEvoy</surname>
              <given-names>MT</given-names>
            </name>
            <name>
              <surname>Gabriel</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Kremers</surname>
              <given-names>HM</given-names>
            </name>
          </person-group>
          <article-title>Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study</article-title>
          <source>Arthritis Rheum</source>
          <year>2009</year>
          <volume>61</volume>
          <issue>2</issue>
          <fpage>233</fpage>
          <lpage>239</lpage>
          <pub-id pub-id-type="pmid">19177544</pub-id>
        </element-citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sandre</surname>
              <given-names>MK</given-names>
            </name>
            <name>
              <surname>Rohekar</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Psoriatic arthritis and nail changes: exploring the relationship</article-title>
          <source>Semin Arthritis Rheum</source>
          <year>2014</year>
          <volume>44</volume>
          <issue>2</issue>
          <fpage>162</fpage>
          <lpage>169</lpage>
          <pub-id pub-id-type="pmid">24932889</pub-id>
        </element-citation>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kaeley</surname>
              <given-names>GS</given-names>
            </name>
            <name>
              <surname>Eder</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Aydin</surname>
              <given-names>SZ</given-names>
            </name>
            <name>
              <surname>Rich</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Bakewell</surname>
              <given-names>CJ</given-names>
            </name>
          </person-group>
          <article-title>Nail psoriasis: diagnosis, assessment, treatment options, and unmet clinical needs</article-title>
          <source>J Rheumatol.</source>
          <year>2021</year>
          <volume>48</volume>
          <issue>8</issue>
          <fpage>1208</fpage>
          <lpage>20</lpage>
          <pub-id pub-id-type="pmid">33589557</pub-id>
        </element-citation>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>de Berker</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Management of psoriatic nail disease</article-title>
          <source>Semin Cutan Med Surg</source>
          <year>2009</year>
          <volume>28</volume>
          <issue>1</issue>
          <fpage>39</fpage>
          <lpage>43</lpage>
          <pub-id pub-id-type="pmid">19341941</pub-id>
        </element-citation>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jiaravuthisan</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Sasseville</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Vender</surname>
              <given-names>RB</given-names>
            </name>
            <name>
              <surname>Murphy</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Muhn</surname>
              <given-names>CY</given-names>
            </name>
          </person-group>
          <article-title>Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy</article-title>
          <source>J Am Acad Dermatol</source>
          <year>2007</year>
          <volume>57</volume>
          <issue>1</issue>
          <fpage>1</fpage>
          <lpage>27</lpage>
          <pub-id pub-id-type="pmid">17572277</pub-id>
        </element-citation>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Raposo</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Torres</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Nail psoriasis as a predictor of the development of psoriatic arthritis</article-title>
          <source>Actas Dermosifiliogr</source>
          <year>2015</year>
          <volume>106</volume>
          <issue>6</issue>
          <fpage>452</fpage>
          <lpage>457</lpage>
          <pub-id pub-id-type="pmid">26026773</pub-id>
        </element-citation>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cimmino</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Seriolo</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Accardo</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Prevalence of nail involvement in nodal osteoarthritis</article-title>
          <source>Clin Rheumatol</source>
          <year>1994</year>
          <volume>13</volume>
          <issue>2</issue>
          <fpage>203</fpage>
          <lpage>206</lpage>
          <pub-id pub-id-type="pmid">8088060</pub-id>
        </element-citation>
      </ref>
      <ref id="CR42">
        <label>42.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kalyoncu</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Gossec</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Nguyen</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Self-reported prevalence of psoriasis and evaluation of the impact on the natural history of hip osteoarthritis: results of a 10 years follow-up study of 507 patients (ECHODIAH study)</article-title>
          <source>Joint Bone Spine</source>
          <year>2009</year>
          <volume>76</volume>
          <issue>4</issue>
          <fpage>389</fpage>
          <lpage>393</lpage>
          <pub-id pub-id-type="pmid">19217337</pub-id>
        </element-citation>
      </ref>
      <ref id="CR43">
        <label>43.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moller</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Perez</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Monfort</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Effectiveness of chondroitin sulphate in patients with concomitant knee osteoarthritis and psoriasis: a randomized, double-blind, placebo-controlled study</article-title>
          <source>Osteoarthritis Cartilage</source>
          <year>2010</year>
          <volume>18</volume>
          <issue>Suppl 1</issue>
          <fpage>S32</fpage>
          <lpage>40</lpage>
          <pub-id pub-id-type="pmid">20399899</pub-id>
        </element-citation>
      </ref>
      <ref id="CR44">
        <label>44.</label>
        <mixed-citation publication-type="other">Wright V. Psoriatic arthritis. A comparative radiographic study of rheumatoid arthritis and arthritis associated with psoriasis. Ann Rheum Dis. 1961;20:123&#x2013;132.</mixed-citation>
      </ref>
      <ref id="CR45">
        <label>45.</label>
        <mixed-citation publication-type="other">Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58(5):851&#x2013;864.</mixed-citation>
      </ref>
      <ref id="CR46">
        <label>46.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sobolewski</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Walecka</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Dopytalska</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Nail involvement in psoriatic arthritis</article-title>
          <source>Reumatologia</source>
          <year>2017</year>
          <volume>55</volume>
          <issue>3</issue>
          <fpage>131</fpage>
          <lpage>135</lpage>
          <pub-id pub-id-type="pmid">28769136</pub-id>
        </element-citation>
      </ref>
      <ref id="CR47">
        <label>47.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gottlieb</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Merola</surname>
              <given-names>JF</given-names>
            </name>
          </person-group>
          <article-title>Axial psoriatic arthritis: an update for dermatologists</article-title>
          <source>J Am Acad Dermatol</source>
          <year>2021</year>
          <volume>84</volume>
          <issue>1</issue>
          <fpage>92</fpage>
          <lpage>101</lpage>
          <pub-id pub-id-type="pmid">32747079</pub-id>
        </element-citation>
      </ref>
      <ref id="CR48">
        <label>48.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gladman</surname>
              <given-names>DD</given-names>
            </name>
          </person-group>
          <article-title>Axial psoriatic arthritis</article-title>
          <source>Curr Rheumatol Rep</source>
          <year>2021</year>
          <volume>23</volume>
          <issue>6</issue>
          <fpage>35</fpage>
          <pub-id pub-id-type="pmid">33909178</pub-id>
        </element-citation>
      </ref>
      <ref id="CR49">
        <label>49.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chandran</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Tolusso</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Cook</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Gladman</surname>
              <given-names>DD</given-names>
            </name>
          </person-group>
          <article-title>Risk factors for axial inflammatory arthritis in patients with psoriatic arthritis</article-title>
          <source>J Rheumatol</source>
          <year>2010</year>
          <volume>37</volume>
          <issue>4</issue>
          <fpage>809</fpage>
          <lpage>815</lpage>
          <pub-id pub-id-type="pmid">20231209</pub-id>
        </element-citation>
      </ref>
      <ref id="CR50">
        <label>50.</label>
        <mixed-citation publication-type="other">Grinnell-Merrick LL, Lydon EJ, Mixon AM, Saalfeld W. Evaluating inflammatory versus mechanical back pain in individuals with psoriatic arthritis: a review of the literature. Rheumatol Ther. 2020;7(4):667&#x2013;84.</mixed-citation>
      </ref>
      <ref id="CR51">
        <label>51.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lindstrom</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Bremander</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Haglund</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Bergman</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Petersson</surname>
              <given-names>IF</given-names>
            </name>
            <name>
              <surname>Jacobsson</surname>
              <given-names>LT</given-names>
            </name>
          </person-group>
          <article-title>Back pain and health status in patients with clinically diagnosed ankylosing spondylitis, psoriatic arthritis and other spondyloarthritis: a cross-sectional population-based study</article-title>
          <source>BMC Musculoskelet Disord</source>
          <year>2016</year>
          <volume>17</volume>
          <fpage>106</fpage>
          <pub-id pub-id-type="pmid">26922375</pub-id>
        </element-citation>
      </ref>
      <ref id="CR52">
        <label>52.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Caso</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Costa</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Atteno</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Simple clinical indicators for early psoriatic arthritis detection</article-title>
          <source>Springerplus</source>
          <year>2014</year>
          <volume>3</volume>
          <fpage>759</fpage>
          <pub-id pub-id-type="pmid">25674484</pub-id>
        </element-citation>
      </ref>
      <ref id="CR53">
        <label>53.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Baraliakos</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Coates</surname>
              <given-names>LC</given-names>
            </name>
            <name>
              <surname>Braun</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>The involvement of the spine in psoriatic arthritis</article-title>
          <source>Clin Exp Rheumatol</source>
          <year>2015</year>
          <volume>33</volume>
          <issue>5 Suppl 93</issue>
          <fpage>S31</fpage>
          <lpage>35</lpage>
          <pub-id pub-id-type="pmid">26471338</pub-id>
        </element-citation>
      </ref>
      <ref id="CR54">
        <label>54.</label>
        <mixed-citation publication-type="other">Sieper J, Rudwaleit M, Baraliakos X, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009;68 Suppl 2:ii1&#x2013;44.</mixed-citation>
      </ref>
      <ref id="CR55">
        <label>55.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sieper</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>van der Heijde</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Landewe</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the assessment of SpondyloArthritis international Society (ASAS)</article-title>
          <source>Ann Rheum Dis</source>
          <year>2009</year>
          <volume>68</volume>
          <issue>6</issue>
          <fpage>784</fpage>
          <lpage>788</lpage>
          <pub-id pub-id-type="pmid">19147614</pub-id>
        </element-citation>
      </ref>
      <ref id="CR56">
        <label>56.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Burgos-Vargas</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Braun</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Inflammatory back pain</article-title>
          <source>Rheum Dis Clin North Am</source>
          <year>2012</year>
          <volume>38</volume>
          <issue>3</issue>
          <fpage>487</fpage>
          <lpage>499</lpage>
          <pub-id pub-id-type="pmid">23083750</pub-id>
        </element-citation>
      </ref>
      <ref id="CR57">
        <label>57.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ledford</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Spine conditions: mechanical and inflammatory low back pain</article-title>
          <source>FP Essent</source>
          <year>2017</year>
          <volume>461</volume>
          <fpage>15</fpage>
          <lpage>20</lpage>
          <pub-id pub-id-type="pmid">29019640</pub-id>
        </element-citation>
      </ref>
      <ref id="CR58">
        <label>58.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Castillo-Gallego</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Aydin</surname>
              <given-names>SZ</given-names>
            </name>
            <name>
              <surname>Emery</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>McGonagle</surname>
              <given-names>DG</given-names>
            </name>
            <name>
              <surname>Marzo-Ortega</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Magnetic resonance imaging assessment of axial psoriatic arthritis: extent of disease relates to HLA-B27</article-title>
          <source>Arthritis Rheum</source>
          <year>2013</year>
          <volume>65</volume>
          <issue>9</issue>
          <fpage>2274</fpage>
          <lpage>2278</lpage>
          <pub-id pub-id-type="pmid">23780792</pub-id>
        </element-citation>
      </ref>
      <ref id="CR59">
        <label>59.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Michelena</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Poddubnyy</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Marzo-Ortega</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Axial psoriatic arthritis: a distinct clinical entity in search of a definition</article-title>
          <source>Rheum Dis Clin North Am</source>
          <year>2020</year>
          <volume>46</volume>
          <issue>2</issue>
          <fpage>327</fpage>
          <lpage>341</lpage>
          <pub-id pub-id-type="pmid">32340705</pub-id>
        </element-citation>
      </ref>
      <ref id="CR60">
        <label>60.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lubrano</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Parsons</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Marchesoni</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The definition and measurement of axial psoriatic arthritis</article-title>
          <source>J Rheumatol Suppl</source>
          <year>2015</year>
          <volume>93</volume>
          <fpage>40</fpage>
          <lpage>42</lpage>
          <pub-id pub-id-type="pmid">26523055</pub-id>
        </element-citation>
      </ref>
      <ref id="CR61">
        <label>61.</label>
        <mixed-citation publication-type="other">Sudol-Szopinska I, Matuszewska G, Kwiatkowska B, Pracon G. Diagnostic imaging of psoriatic arthritis. Part I: etiopathogenesis, classifications and radiographic features. J Ultrason. 2016;16(64):65&#x2013;77.</mixed-citation>
      </ref>
      <ref id="CR62">
        <label>62.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Labitigan</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bahce-Altuntas</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kremer</surname>
              <given-names>JM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Higher rates and clustering of abnormal lipids, obesity, and diabetes mellitus in psoriatic arthritis compared with rheumatoid arthritis</article-title>
          <source>Arthritis Care Res (Hoboken)</source>
          <year>2014</year>
          <volume>66</volume>
          <issue>4</issue>
          <fpage>600</fpage>
          <lpage>607</lpage>
          <pub-id pub-id-type="pmid">24115739</pub-id>
        </element-citation>
      </ref>
      <ref id="CR63">
        <label>63.</label>
        <mixed-citation publication-type="other">Kaine J, Song X, Kim G, Hur P, Palmer JB. Higher incidence rates of comorbidities in patients with psoriatic arthritis compared with the general population using U.S. administrative claims data. J Manag Care Spec Pharm. 2019;25(1):122&#x2013;132.</mixed-citation>
      </ref>
      <ref id="CR64">
        <label>64.</label>
        <mixed-citation publication-type="other">Shah K, Paris M, Mellars L, Changolkar A, Mease PJ. Real-world burden of comorbidities in US patients with psoriatic arthritis. RMD Open. 2017;3(2):e000588.</mixed-citation>
      </ref>
      <ref id="CR65">
        <label>65.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jamnitski</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Visman</surname>
              <given-names>IM</given-names>
            </name>
            <name>
              <surname>Peters</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Boers</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Dijkmans</surname>
              <given-names>BA</given-names>
            </name>
            <name>
              <surname>Nurmohamed</surname>
              <given-names>MT</given-names>
            </name>
          </person-group>
          <article-title>Prevalence of cardiovascular diseases in psoriatic arthritis resembles that of rheumatoid arthritis</article-title>
          <source>Ann Rheum Dis</source>
          <year>2011</year>
          <volume>70</volume>
          <issue>5</issue>
          <fpage>875</fpage>
          <lpage>876</lpage>
          <pub-id pub-id-type="pmid">20956406</pub-id>
        </element-citation>
      </ref>
      <ref id="CR66">
        <label>66.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mease</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Rebello</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Comparative disease burden in patients with rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis: data from two Corrona registries</article-title>
          <source>Rheumatol Ther</source>
          <year>2019</year>
          <volume>6</volume>
          <issue>4</issue>
          <fpage>529</fpage>
          <lpage>542</lpage>
          <pub-id pub-id-type="pmid">31529278</pub-id>
        </element-citation>
      </ref>
      <ref id="CR67">
        <label>67.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ogdie</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Haynes</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study</article-title>
          <source>Ann Rheum Dis</source>
          <year>2015</year>
          <volume>74</volume>
          <issue>2</issue>
          <fpage>326</fpage>
          <lpage>332</lpage>
          <pub-id pub-id-type="pmid">25351522</pub-id>
        </element-citation>
      </ref>
      <ref id="CR68">
        <label>68.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Canete</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Mease</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>The link between obesity and psoriatic arthritis</article-title>
          <source>Ann Rheum Dis</source>
          <year>2012</year>
          <volume>71</volume>
          <issue>8</issue>
          <fpage>1265</fpage>
          <lpage>1266</lpage>
          <pub-id pub-id-type="pmid">22798633</pub-id>
        </element-citation>
      </ref>
      <ref id="CR69">
        <label>69.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Deveza</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Melo</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Yamato</surname>
              <given-names>TP</given-names>
            </name>
            <name>
              <surname>Mills</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ravi</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Hunter</surname>
              <given-names>DJ</given-names>
            </name>
          </person-group>
          <article-title>Knee osteoarthritis phenotypes and their relevance for outcomes: a systematic review</article-title>
          <source>Osteoarthritis Cartilage</source>
          <year>2017</year>
          <volume>25</volume>
          <issue>12</issue>
          <fpage>1926</fpage>
          <lpage>1941</lpage>
          <pub-id pub-id-type="pmid">28847624</pub-id>
        </element-citation>
      </ref>
      <ref id="CR70">
        <label>70.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schieir</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Tosevski</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Glazier</surname>
              <given-names>RH</given-names>
            </name>
            <name>
              <surname>Hogg-Johnson</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Badley</surname>
              <given-names>EM</given-names>
            </name>
          </person-group>
          <article-title>Incident myocardial infarction associated with major types of arthritis in the general population: a systematic review and meta-analysis</article-title>
          <source>Ann Rheum Dis</source>
          <year>2017</year>
          <volume>76</volume>
          <issue>8</issue>
          <fpage>1396</fpage>
          <lpage>1404</lpage>
          <pub-id pub-id-type="pmid">28219882</pub-id>
        </element-citation>
      </ref>
      <ref id="CR71">
        <label>71.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yusuf</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Metabolic factors in osteoarthritis: obese people do not walk on their hands</article-title>
          <source>Arthritis Res Ther</source>
          <year>2012</year>
          <volume>14</volume>
          <issue>4</issue>
          <fpage>123</fpage>
          <pub-id pub-id-type="pmid">22809017</pub-id>
        </element-citation>
      </ref>
      <ref id="CR72">
        <label>72.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Swain</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sarmanova</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Coupland</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Doherty</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Comorbidities in osteoarthritis: a systematic review and meta-analysis of observational studies</article-title>
          <source>Arthritis Care Res (Hoboken)</source>
          <year>2020</year>
          <volume>72</volume>
          <issue>7</issue>
          <fpage>991</fpage>
          <lpage>1000</lpage>
          <pub-id pub-id-type="pmid">31207113</pub-id>
        </element-citation>
      </ref>
      <ref id="CR73">
        <label>73.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>van der Heijde</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Gladman</surname>
              <given-names>DD</given-names>
            </name>
            <name>
              <surname>Kavanaugh</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mease</surname>
              <given-names>PJ</given-names>
            </name>
          </person-group>
          <article-title>Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research</article-title>
          <source>Arthritis Res Ther</source>
          <year>2020</year>
          <volume>22</volume>
          <issue>1</issue>
          <fpage>18</fpage>
          <pub-id pub-id-type="pmid">32014044</pub-id>
        </element-citation>
      </ref>
      <ref id="CR74">
        <label>74.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wassenberg</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Radiographic scoring methods in psoriatic arthritis</article-title>
          <source>Clin Exp Rheumatol</source>
          <year>2015</year>
          <volume>33</volume>
          <issue>5 Suppl 93</issue>
          <fpage>S55</fpage>
          <lpage>59</lpage>
          <pub-id pub-id-type="pmid">26472605</pub-id>
        </element-citation>
      </ref>
      <ref id="CR75">
        <label>75.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Braga</surname>
              <given-names>MV</given-names>
            </name>
            <name>
              <surname>de Oliveira</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Vasconcelos</surname>
              <given-names>AHC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Prevalence of sacroiliitis and acute and structural changes on MRI in patients with psoriatic arthritis</article-title>
          <source>Sci Rep</source>
          <year>2020</year>
          <volume>10</volume>
          <issue>1</issue>
          <fpage>11580</fpage>
          <pub-id pub-id-type="pmid">32665619</pub-id>
        </element-citation>
      </ref>
      <ref id="CR76">
        <label>76.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ritchlin</surname>
              <given-names>CT</given-names>
            </name>
            <name>
              <surname>Colbert</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Gladman</surname>
              <given-names>DD</given-names>
            </name>
          </person-group>
          <article-title>Psoriatic arthritis</article-title>
          <source>N Engl J Med</source>
          <year>2017</year>
          <volume>376</volume>
          <issue>10</issue>
          <fpage>957</fpage>
          <lpage>970</lpage>
          <pub-id pub-id-type="pmid">28273019</pub-id>
        </element-citation>
      </ref>
      <ref id="CR77">
        <label>77.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>D'Agostino</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Terslev</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Imaging evaluation of the entheses: ultrasonography, MRI, and scoring of evaluation</article-title>
          <source>Rheum Dis Clin North Am</source>
          <year>2016</year>
          <volume>42</volume>
          <issue>4</issue>
          <fpage>679</fpage>
          <lpage>693</lpage>
          <pub-id pub-id-type="pmid">27742021</pub-id>
        </element-citation>
      </ref>
      <ref id="CR78">
        <label>78.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Watad</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Eshed</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>McGonagle</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Lessons learned from imaging on enthesitis in psoriatic arthritis</article-title>
          <source>Isr Med Assoc J</source>
          <year>2017</year>
          <volume>19</volume>
          <issue>11</issue>
          <fpage>708</fpage>
          <lpage>711</lpage>
          <pub-id pub-id-type="pmid">29185286</pub-id>
        </element-citation>
      </ref>
      <ref id="CR79">
        <label>79.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ichikawa</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Taniguchi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kobayashi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Yamanaka</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Performance of hands and feet radiographs in differentiation of psoriatic arthritis from rheumatoid arthritis</article-title>
          <source>Int J Rheum Dis</source>
          <year>2012</year>
          <volume>15</volume>
          <issue>5</issue>
          <fpage>462</fpage>
          <lpage>467</lpage>
          <pub-id pub-id-type="pmid">23083036</pub-id>
        </element-citation>
      </ref>
      <ref id="CR80">
        <label>80.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bakewell</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Aydin</surname>
              <given-names>SZ</given-names>
            </name>
            <name>
              <surname>Ranganath</surname>
              <given-names>VK</given-names>
            </name>
            <name>
              <surname>Eder</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Kaeley</surname>
              <given-names>GS</given-names>
            </name>
          </person-group>
          <article-title>Imaging techniques: options for the diagnosis and monitoring of treatment of enthesitis in psoriatic arthritis</article-title>
          <source>J Rheumatol</source>
          <year>2020</year>
          <volume>47</volume>
          <issue>7</issue>
          <fpage>973</fpage>
          <lpage>982</lpage>
          <pub-id pub-id-type="pmid">31676700</pub-id>
        </element-citation>
      </ref>
      <ref id="CR81">
        <label>81.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Naredo</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Moller</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>de Miguel</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>High prevalence of ultrasonographic synovitis and enthesopathy in patients with psoriasis without psoriatic arthritis: a prospective case-control study</article-title>
          <source>Rheumatology (Oxford)</source>
          <year>2011</year>
          <volume>50</volume>
          <issue>10</issue>
          <fpage>1838</fpage>
          <lpage>1848</lpage>
          <pub-id pub-id-type="pmid">21700682</pub-id>
        </element-citation>
      </ref>
      <ref id="CR82">
        <label>82.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zuliani</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Zabotti</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Errichetti</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Ultrasonographic detection of subclinical enthesitis and synovitis: a possible stratification of psoriatic patients without clinical musculoskeletal involvement</article-title>
          <source>Clin Exp Rheumatol</source>
          <year>2019</year>
          <volume>37</volume>
          <issue>4</issue>
          <fpage>593</fpage>
          <lpage>599</lpage>
          <pub-id pub-id-type="pmid">30620282</pub-id>
        </element-citation>
      </ref>
      <ref id="CR83">
        <label>83.</label>
        <mixed-citation publication-type="other">D'Agostino MA, Terslev L, Aegerter P, et al. Scoring ultrasound synovitis in rheumatoid arthritis: a EULAR-OMERACT ultrasound taskforce&#x2014;Part 1: definition and development of a standardised, consensus-based scoring system. RMD Open. 2017;3(1):e000428.</mixed-citation>
      </ref>
      <ref id="CR84">
        <label>84.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bandinelli</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Denaro</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Prignano</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Collaku</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Ciancio</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Matucci-Cerinic</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Ultrasonographic wrist and hand abnormalities in early psoriatic arthritis patients: correlation with clinical, dermatological, serological and genetic indices</article-title>
          <source>Clin Exp Rheumatol</source>
          <year>2015</year>
          <volume>33</volume>
          <issue>3</issue>
          <fpage>330</fpage>
          <lpage>335</lpage>
          <pub-id pub-id-type="pmid">25797649</pub-id>
        </element-citation>
      </ref>
      <ref id="CR85">
        <label>85.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Freeston</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Coates</surname>
              <given-names>LC</given-names>
            </name>
            <name>
              <surname>Nam</surname>
              <given-names>JL</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Is there subclinical synovitis in early psoriatic arthritis? A clinical comparison with gray-scale and power Doppler ultrasound</article-title>
          <source>Arthritis Care Res (Hoboken)</source>
          <year>2014</year>
          <volume>66</volume>
          <issue>3</issue>
          <fpage>432</fpage>
          <lpage>439</lpage>
          <pub-id pub-id-type="pmid">24022986</pub-id>
        </element-citation>
      </ref>
      <ref id="CR86">
        <label>86.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kamel</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Eid</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Mansour</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Ultrasound detection of heel enthesitis: a comparison with magnetic resonance imaging</article-title>
          <source>J Rheumatol</source>
          <year>2003</year>
          <volume>30</volume>
          <issue>4</issue>
          <fpage>774</fpage>
          <lpage>778</lpage>
          <pub-id pub-id-type="pmid">12672198</pub-id>
        </element-citation>
      </ref>
      <ref id="CR87">
        <label>87.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Balint</surname>
              <given-names>PV</given-names>
            </name>
            <name>
              <surname>Kane</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Wilson</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>McInnes</surname>
              <given-names>IB</given-names>
            </name>
            <name>
              <surname>Sturrock</surname>
              <given-names>RD</given-names>
            </name>
          </person-group>
          <article-title>Ultrasonography of entheseal insertions in the lower limb in spondyloarthropathy</article-title>
          <source>Ann Rheum Dis</source>
          <year>2002</year>
          <volume>61</volume>
          <issue>10</issue>
          <fpage>905</fpage>
          <lpage>910</lpage>
          <pub-id pub-id-type="pmid">12228161</pub-id>
        </element-citation>
      </ref>
      <ref id="CR88">
        <label>88.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tom</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Zhong</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Cook</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Aydin</surname>
              <given-names>SZ</given-names>
            </name>
            <name>
              <surname>Kaeley</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Eder</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Development of a preliminary ultrasonographic enthesitis score in psoriatic arthritis&#x2014;GRAPPA Ultrasound Working Group</article-title>
          <source>J Rheumatol</source>
          <year>2019</year>
          <volume>46</volume>
          <issue>4</issue>
          <fpage>384</fpage>
          <lpage>390</lpage>
          <pub-id pub-id-type="pmid">30323008</pub-id>
        </element-citation>
      </ref>
      <ref id="CR89">
        <label>89.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Polachek</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Chandran</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Gladman</surname>
              <given-names>DD</given-names>
            </name>
          </person-group>
          <article-title>Clinical enthesitis in a prospective longitudinal psoriatic arthritis cohort: incidence, prevalence, characteristics, and outcome</article-title>
          <source>Arthritis Care Res (Hoboken)</source>
          <year>2017</year>
          <volume>69</volume>
          <issue>11</issue>
          <fpage>1685</fpage>
          <lpage>1691</lpage>
          <pub-id pub-id-type="pmid">27998023</pub-id>
        </element-citation>
      </ref>
      <ref id="CR90">
        <label>90.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gutierrez</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Filippucci</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Salaffi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Di Geso</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Grassi</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Differential diagnosis between rheumatoid arthritis and psoriatic arthritis: the value of ultrasound findings at metacarpophalangeal joints level</article-title>
          <source>Ann Rheum Dis</source>
          <year>2011</year>
          <volume>70</volume>
          <issue>6</issue>
          <fpage>1111</fpage>
          <lpage>1114</lpage>
          <pub-id pub-id-type="pmid">21406459</pub-id>
        </element-citation>
      </ref>
      <ref id="CR91">
        <label>91.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wiell</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Szkudlarek</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hasselquist</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Ultrasonography, magnetic resonance imaging, radiography, and clinical assessment of inflammatory and destructive changes in fingers and toes of patients with psoriatic arthritis</article-title>
          <source>Arthritis Res Ther</source>
          <year>2007</year>
          <volume>9</volume>
          <issue>6</issue>
          <fpage>R119</fpage>
          <pub-id pub-id-type="pmid">18001463</pub-id>
        </element-citation>
      </ref>
      <ref id="CR92">
        <label>92.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ostergaard</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>McQueen</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Wiell</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The OMERACT psoriatic arthritis magnetic resonance imaging scoring system (PsAMRIS): definitions of key pathologies, suggested MRI sequences, and preliminary scoring system for PsA hands</article-title>
          <source>J Rheumatol</source>
          <year>2009</year>
          <volume>36</volume>
          <issue>8</issue>
          <fpage>1816</fpage>
          <lpage>1824</lpage>
          <pub-id pub-id-type="pmid">19671819</pub-id>
        </element-citation>
      </ref>
      <ref id="CR93">
        <label>93.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sankowski</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Lebkowska</surname>
              <given-names>UM</given-names>
            </name>
            <name>
              <surname>Cwikla</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Walecka</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Walecki</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>The comparison of efficacy of different imaging techniques (conventional radiography, ultrasonography, magnetic resonance) in assessment of wrist joints and metacarpophalangeal joints in patients with psoriatic arthritis</article-title>
          <source>Pol J Radiol</source>
          <year>2013</year>
          <volume>78</volume>
          <issue>1</issue>
          <fpage>18</fpage>
          <lpage>29</lpage>
          <pub-id pub-id-type="pmid">23494635</pub-id>
        </element-citation>
      </ref>
      <ref id="CR94">
        <label>94.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mathew</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Coates</surname>
              <given-names>LC</given-names>
            </name>
            <name>
              <surname>Danda</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Conaghan</surname>
              <given-names>PG</given-names>
            </name>
          </person-group>
          <article-title>Psoriatic arthritis: lessons from imaging studies and implications for therapy</article-title>
          <source>Expert Rev Clin Immunol</source>
          <year>2017</year>
          <volume>13</volume>
          <issue>2</issue>
          <fpage>133</fpage>
          <lpage>142</lpage>
          <pub-id pub-id-type="pmid">27487860</pub-id>
        </element-citation>
      </ref>
      <ref id="CR95">
        <label>95.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Narvaez</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Narvaez</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>de Albert</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gomez-Vaquero</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Nolla</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <article-title>Can magnetic resonance imaging of the hand and wrist differentiate between rheumatoid arthritis and psoriatic arthritis in the early stages of the disease?</article-title>
          <source>Semin Arthritis Rheum</source>
          <year>2012</year>
          <volume>42</volume>
          <issue>3</issue>
          <fpage>234</fpage>
          <lpage>245</lpage>
          <pub-id pub-id-type="pmid">22595641</pub-id>
        </element-citation>
      </ref>
      <ref id="CR96">
        <label>96.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Braum</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>McGonagle</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Bruns</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Characterisation of hand small joints arthropathy using high-resolution MRI&#x2014;limited discrimination between osteoarthritis and psoriatic arthritis</article-title>
          <source>Eur Radiol</source>
          <year>2013</year>
          <volume>23</volume>
          <issue>6</issue>
          <fpage>1686</fpage>
          <lpage>1693</lpage>
          <pub-id pub-id-type="pmid">23300035</pub-id>
        </element-citation>
      </ref>
      <ref id="CR97">
        <label>97.</label>
        <mixed-citation publication-type="other">Felbo SK, Terslev L, Ostergaard M. Imaging in peripheral and axial psoriatic arthritis: contributions to diagnosis, follow-up, prognosis and knowledge of pathogenesis. Clin Exp Rheumatol. 2018;36 Suppl 114(5):24&#x2013;34.</mixed-citation>
      </ref>
      <ref id="CR98">
        <label>98.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Forney</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Winalski</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Schils</surname>
              <given-names>JP</given-names>
            </name>
          </person-group>
          <article-title>Magnetic resonance imaging of inflammatory arthropathies of peripheral joints</article-title>
          <source>Top Magn Reson Imaging</source>
          <year>2011</year>
          <volume>22</volume>
          <issue>2</issue>
          <fpage>45</fpage>
          <lpage>59</lpage>
          <pub-id pub-id-type="pmid">22648080</pub-id>
        </element-citation>
      </ref>
      <ref id="CR99">
        <label>99.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schraml</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Schwenzer</surname>
              <given-names>NF</given-names>
            </name>
            <name>
              <surname>Martirosian</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Assessment of synovitis in erosive osteoarthritis of the hand using DCE-MRI and comparison with that in its major mimic, the psoriatic arthritis</article-title>
          <source>Acad Radiol</source>
          <year>2011</year>
          <volume>18</volume>
          <issue>7</issue>
          <fpage>804</fpage>
          <lpage>809</lpage>
          <pub-id pub-id-type="pmid">21419667</pub-id>
        </element-citation>
      </ref>
      <ref id="CR100">
        <label>100.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bagel</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Schwartzman</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Enthesitis and dactylitis in psoriatic disease: a guide for dermatologists</article-title>
          <source>Am J Clin Dermatol</source>
          <year>2018</year>
          <volume>19</volume>
          <issue>6</issue>
          <fpage>839</fpage>
          <lpage>852</lpage>
          <pub-id pub-id-type="pmid">30117018</pub-id>
        </element-citation>
      </ref>
      <ref id="CR101">
        <label>101.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mandl</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Navarro-Compan</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Terslev</surname>
              <given-names>L</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>EULAR recommendations for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice</article-title>
          <source>Ann Rheum Dis</source>
          <year>2015</year>
          <volume>74</volume>
          <issue>7</issue>
          <fpage>1327</fpage>
          <lpage>1339</lpage>
          <pub-id pub-id-type="pmid">25837448</pub-id>
        </element-citation>
      </ref>
      <ref id="CR102">
        <label>102.</label>
        <mixed-citation publication-type="other">Veale DJ, Fearon U. What makes psoriatic and rheumatoid arthritis so different? RMD Open. 2015;1(1):e000025.</mixed-citation>
      </ref>
      <ref id="CR103">
        <label>103.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Donmez</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Pamuk</surname>
              <given-names>ON</given-names>
            </name>
            <name>
              <surname>Akker</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ak</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Clinical features and types of articular involvement in patients with psoriatic arthritis</article-title>
          <source>Clin Rheumatol</source>
          <year>2015</year>
          <volume>34</volume>
          <issue>6</issue>
          <fpage>1091</fpage>
          <lpage>1096</lpage>
          <pub-id pub-id-type="pmid">25066919</pub-id>
        </element-citation>
      </ref>
      <ref id="CR104">
        <label>104.</label>
        <mixed-citation publication-type="other">Ogdie A, Coates LC, Gladman DD. Treatment guidelines in psoriatic arthritis. Rheumatology (Oxford). 2020;59(Supplement_1):i37-i46.</mixed-citation>
      </ref>
      <ref id="CR105">
        <label>105.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gossec</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Baraliakos</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Kerschbaumer</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update</article-title>
          <source>Ann Rheum Dis</source>
          <year>2020</year>
          <volume>79</volume>
          <issue>6</issue>
          <fpage>700</fpage>
          <lpage>712</lpage>
          <pub-id pub-id-type="pmid">32434812</pub-id>
        </element-citation>
      </ref>
      <ref id="CR106">
        <label>106.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Generali</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Scire</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Favalli</surname>
              <given-names>EG</given-names>
            </name>
            <name>
              <surname>Selmi</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Biomarkers in psoriatic arthritis: a systematic literature review</article-title>
          <source>Expert Rev Clin Immunol</source>
          <year>2016</year>
          <volume>12</volume>
          <issue>6</issue>
          <fpage>651</fpage>
          <lpage>660</lpage>
          <pub-id pub-id-type="pmid">26821681</pub-id>
        </element-citation>
      </ref>
      <ref id="CR107">
        <label>107.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Winchester</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Minevich</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Steshenko</surname>
              <given-names>V</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>HLA associations reveal genetic heterogeneity in psoriatic arthritis and in the psoriasis phenotype</article-title>
          <source>Arthritis Rheum</source>
          <year>2012</year>
          <volume>64</volume>
          <issue>4</issue>
          <fpage>1134</fpage>
          <lpage>1144</lpage>
          <pub-id pub-id-type="pmid">22006066</pub-id>
        </element-citation>
      </ref>
      <ref id="CR108">
        <label>108.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Haroon</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Winchester</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Giles</surname>
              <given-names>JT</given-names>
            </name>
            <name>
              <surname>Heffernan</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>FitzGerald</surname>
              <given-names>O</given-names>
            </name>
          </person-group>
          <article-title>Certain class I HLA alleles and haplotypes implicated in susceptibility play a role in determining specific features of the psoriatic arthritis phenotype</article-title>
          <source>Ann Rheum Dis</source>
          <year>2016</year>
          <volume>75</volume>
          <issue>1</issue>
          <fpage>155</fpage>
          <lpage>162</lpage>
          <pub-id pub-id-type="pmid">25261574</pub-id>
        </element-citation>
      </ref>
      <ref id="CR109">
        <label>109.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Queiro</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Morante</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Cabezas</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Acasuso</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>HLA-B27 and psoriatic disease: a modern view of an old relationship</article-title>
          <source>Rheumatology (Oxford)</source>
          <year>2016</year>
          <volume>55</volume>
          <issue>2</issue>
          <fpage>221</fpage>
          <lpage>229</lpage>
          <pub-id pub-id-type="pmid">26289052</pub-id>
        </element-citation>
      </ref>
      <ref id="CR110">
        <label>110.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Silman</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Pearson</surname>
              <given-names>JE</given-names>
            </name>
          </person-group>
          <article-title>Epidemiology and genetics of rheumatoid arthritis</article-title>
          <source>Arthritis Res</source>
          <year>2002</year>
          <volume>4</volume>
          <issue>Suppl 3</issue>
          <fpage>S265</fpage>
          <lpage>272</lpage>
          <pub-id pub-id-type="pmid">12110146</pub-id>
        </element-citation>
      </ref>
      <ref id="CR111">
        <label>111.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ahmad</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Marshall</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Jewell</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Genetics of inflammatory bowel disease: the role of the HLA complex</article-title>
          <source>World J Gastroenterol</source>
          <year>2006</year>
          <volume>12</volume>
          <issue>23</issue>
          <fpage>3628</fpage>
          <lpage>3635</lpage>
          <pub-id pub-id-type="pmid">16773677</pub-id>
        </element-citation>
      </ref>
      <ref id="CR112">
        <label>112.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bazzoni</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Beutler</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>The tumor necrosis factor ligand and receptor families</article-title>
          <source>N Engl J Med</source>
          <year>1996</year>
          <volume>334</volume>
          <issue>26</issue>
          <fpage>1717</fpage>
          <lpage>1725</lpage>
          <pub-id pub-id-type="pmid">8637518</pub-id>
        </element-citation>
      </ref>
      <ref id="CR113">
        <label>113.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bradley</surname>
              <given-names>JR</given-names>
            </name>
          </person-group>
          <article-title>TNF-mediated inflammatory disease</article-title>
          <source>J Pathol</source>
          <year>2008</year>
          <volume>214</volume>
          <issue>2</issue>
          <fpage>149</fpage>
          <lpage>160</lpage>
          <pub-id pub-id-type="pmid">18161752</pub-id>
        </element-citation>
      </ref>
      <ref id="CR114">
        <label>114.</label>
        <mixed-citation publication-type="other">van Kuijk AW, Reinders-Blankert P, Smeets TJ, Dijkmans BA, Tak PP. Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. Ann Rheum Dis. 2006;65(12):1551&#x2013;1557.</mixed-citation>
      </ref>
      <ref id="CR115">
        <label>115.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Blauvelt</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Chiricozzi</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>The Immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis</article-title>
          <source>Clin Rev Allergy Immunol</source>
          <year>2018</year>
          <volume>55</volume>
          <issue>3</issue>
          <fpage>379</fpage>
          <lpage>390</lpage>
          <pub-id pub-id-type="pmid">30109481</pub-id>
        </element-citation>
      </ref>
      <ref id="CR116">
        <label>116.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>de Vlam</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Gottlieb</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Mease</surname>
              <given-names>PJ</given-names>
            </name>
          </person-group>
          <article-title>Current concepts in psoriatic arthritis: pathogenesis and management</article-title>
          <source>Acta Derm Venereol</source>
          <year>2014</year>
          <volume>94</volume>
          <issue>6</issue>
          <fpage>627</fpage>
          <lpage>634</lpage>
          <pub-id pub-id-type="pmid">24573106</pub-id>
        </element-citation>
      </ref>
      <ref id="CR117">
        <label>117.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Raychaudhuri</surname>
              <given-names>SP</given-names>
            </name>
          </person-group>
          <article-title>Role of IL-17 in psoriasis and psoriatic arthritis</article-title>
          <source>Clin Rev Allergy Immunol</source>
          <year>2013</year>
          <volume>44</volume>
          <issue>2</issue>
          <fpage>183</fpage>
          <lpage>193</lpage>
          <pub-id pub-id-type="pmid">22362575</pub-id>
        </element-citation>
      </ref>
      <ref id="CR118">
        <label>118.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Raychaudhuri</surname>
              <given-names>SP</given-names>
            </name>
            <name>
              <surname>Raychaudhuri</surname>
              <given-names>SK</given-names>
            </name>
            <name>
              <surname>Genovese</surname>
              <given-names>MC</given-names>
            </name>
          </person-group>
          <article-title>IL-17 receptor and its functional significance in psoriatic arthritis</article-title>
          <source>Mol Cell Biochem</source>
          <year>2012</year>
          <volume>359</volume>
          <issue>1&#x2013;2</issue>
          <fpage>419</fpage>
          <lpage>429</lpage>
          <pub-id pub-id-type="pmid">21894442</pub-id>
        </element-citation>
      </ref>
      <ref id="CR119">
        <label>119.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Filer</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ho</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>RL</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Investigation of association of the IL12B and IL23R genes with psoriatic arthritis</article-title>
          <source>Arthritis Rheum</source>
          <year>2008</year>
          <volume>58</volume>
          <issue>12</issue>
          <fpage>3705</fpage>
          <lpage>3709</lpage>
          <pub-id pub-id-type="pmid">19035472</pub-id>
        </element-citation>
      </ref>
      <ref id="CR120">
        <label>120.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Huffmeier</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Lascorz</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bohm</surname>
              <given-names>B</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Genetic variants of the IL-23R pathway: association with psoriatic arthritis and psoriasis vulgaris, but no specific risk factor for arthritis</article-title>
          <source>J Invest Dermatol</source>
          <year>2009</year>
          <volume>129</volume>
          <issue>2</issue>
          <fpage>355</fpage>
          <lpage>358</lpage>
          <pub-id pub-id-type="pmid">18800148</pub-id>
        </element-citation>
      </ref>
      <ref id="CR121">
        <label>121.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Athie-Morales</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Smits</surname>
              <given-names>HH</given-names>
            </name>
            <name>
              <surname>Cantrell</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Hilkens</surname>
              <given-names>CM</given-names>
            </name>
          </person-group>
          <article-title>Sustained IL-12 signaling is required for Th1 development</article-title>
          <source>J Immunol</source>
          <year>2004</year>
          <volume>172</volume>
          <issue>1</issue>
          <fpage>61</fpage>
          <lpage>69</lpage>
          <pub-id pub-id-type="pmid">14688310</pub-id>
        </element-citation>
      </ref>
      <ref id="CR122">
        <label>122.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sherlock</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Joyce-Shaikh</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Turner</surname>
              <given-names>SP</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>IL-23 induces spondyloarthropathy by acting on ROR-&#x3B3;+ CD3+CD4-CD8- entheseal resident T cells</article-title>
          <source>Nat Med.</source>
          <year>2012</year>
          <volume>18</volume>
          <issue>7</issue>
          <fpage>1069</fpage>
          <lpage>76</lpage>
          <pub-id pub-id-type="pmid">22772566</pub-id>
        </element-citation>
      </ref>
      <ref id="CR123">
        <label>123.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lories</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>McInnes</surname>
              <given-names>IB</given-names>
            </name>
          </person-group>
          <article-title>Primed for inflammation: enthesis-resident T&#xA0;cells</article-title>
          <source>Nat Med</source>
          <year>2012</year>
          <volume>18</volume>
          <issue>7</issue>
          <fpage>1018</fpage>
          <lpage>1019</lpage>
          <pub-id pub-id-type="pmid">22772553</pub-id>
        </element-citation>
      </ref>
      <ref id="CR124">
        <label>124.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Choy</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis</article-title>
          <source>Rheumatology (Oxford)</source>
          <year>2012</year>
          <volume>51</volume>
          <issue>Suppl 5</issue>
          <fpage>v3</fpage>
          <lpage>11</lpage>
          <pub-id pub-id-type="pmid">22718924</pub-id>
        </element-citation>
      </ref>
      <ref id="CR125">
        <label>125.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McInnes</surname>
              <given-names>IB</given-names>
            </name>
            <name>
              <surname>Schett</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Cytokines in the pathogenesis of rheumatoid arthritis</article-title>
          <source>Nat Rev Immunol</source>
          <year>2007</year>
          <volume>7</volume>
          <issue>6</issue>
          <fpage>429</fpage>
          <lpage>442</lpage>
          <pub-id pub-id-type="pmid">17525752</pub-id>
        </element-citation>
      </ref>
      <ref id="CR126">
        <label>126.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Smolen</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Steiner</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Therapeutic strategies for rheumatoid arthritis</article-title>
          <source>Nat Rev Drug Discov</source>
          <year>2003</year>
          <volume>2</volume>
          <issue>6</issue>
          <fpage>473</fpage>
          <lpage>488</lpage>
          <pub-id pub-id-type="pmid">12776222</pub-id>
        </element-citation>
      </ref>
      <ref id="CR127">
        <label>127.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Livshits</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Zhai</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Hart</surname>
              <given-names>DJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Interleukin-6 is a significant predictor of radiographic knee osteoarthritis: The Chingford Study</article-title>
          <source>Arthritis Rheum</source>
          <year>2009</year>
          <volume>60</volume>
          <issue>7</issue>
          <fpage>2037</fpage>
          <lpage>2045</lpage>
          <pub-id pub-id-type="pmid">19565477</pub-id>
        </element-citation>
      </ref>
      <ref id="CR128">
        <label>128.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Celis</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Planell</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Fernandez-Sueiro</surname>
              <given-names>JL</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Synovial cytokine expression in psoriatic arthritis and associations with lymphoid neogenesis and clinical features</article-title>
          <source>Arthritis Res Ther</source>
          <year>2012</year>
          <volume>14</volume>
          <issue>2</issue>
          <fpage>R93</fpage>
          <pub-id pub-id-type="pmid">22541888</pub-id>
        </element-citation>
      </ref>
      <ref id="CR129">
        <label>129.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dinarello</surname>
              <given-names>CA</given-names>
            </name>
          </person-group>
          <article-title>Overview of the interleukin-1 family of ligands and receptors</article-title>
          <source>Semin Immunol</source>
          <year>2013</year>
          <volume>25</volume>
          <issue>6</issue>
          <fpage>389</fpage>
          <lpage>393</lpage>
          <pub-id pub-id-type="pmid">24275600</pub-id>
        </element-citation>
      </ref>
      <ref id="CR130">
        <label>130.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mueller</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Tuan</surname>
              <given-names>RS</given-names>
            </name>
          </person-group>
          <article-title>Anabolic/catabolic balance in pathogenesis of osteoarthritis: identifying molecular targets</article-title>
          <source>PM R</source>
          <year>2011</year>
          <volume>3</volume>
          <issue>6 Suppl 1</issue>
          <fpage>S3</fpage>
          <lpage>11</lpage>
          <pub-id pub-id-type="pmid">21703577</pub-id>
        </element-citation>
      </ref>
      <ref id="CR131">
        <label>131.</label>
        <mixed-citation publication-type="other">Wojdasiewicz P, Poniatowski LA, Szukiewicz D. The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of osteoarthritis. Mediators Inflamm. 2014;2014:561459.</mixed-citation>
      </ref>
      <ref id="CR132">
        <label>132.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dinarello</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>van der Meer</surname>
              <given-names>JW</given-names>
            </name>
          </person-group>
          <article-title>Treating inflammation by blocking interleukin-1 in humans</article-title>
          <source>Semin Immunol</source>
          <year>2013</year>
          <volume>25</volume>
          <issue>6</issue>
          <fpage>469</fpage>
          <lpage>484</lpage>
          <pub-id pub-id-type="pmid">24275598</pub-id>
        </element-citation>
      </ref>
      <ref id="CR133">
        <label>133.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Avdeeva</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Rubtsov</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Dyikanov</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Popkova</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Nasonov</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Regulatory T&#xA0;cells in patients with early untreated rheumatoid arthritis: phenotypic changes in the course of methotrexate treatment</article-title>
          <source>Biochimie</source>
          <year>2020</year>
          <volume>174</volume>
          <fpage>9</fpage>
          <lpage>17</lpage>
          <pub-id pub-id-type="pmid">32275944</pub-id>
        </element-citation>
      </ref>
      <ref id="CR134">
        <label>134.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Choy</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>T&#xA0;cells in psoriatic arthritis</article-title>
          <source>Curr Rheumatol Rep</source>
          <year>2007</year>
          <volume>9</volume>
          <issue>6</issue>
          <fpage>437</fpage>
          <lpage>441</lpage>
          <pub-id pub-id-type="pmid">18177595</pub-id>
        </element-citation>
      </ref>
      <ref id="CR135">
        <label>135.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Diani</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Casciano</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Marongiu</surname>
              <given-names>L</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Increased frequency of activated CD8(+) T&#xA0;cell effectors in patients with psoriatic arthritis</article-title>
          <source>Sci Rep</source>
          <year>2019</year>
          <volume>9</volume>
          <issue>1</issue>
          <fpage>10870</fpage>
          <pub-id pub-id-type="pmid">31350460</pub-id>
        </element-citation>
      </ref>
      <ref id="CR136">
        <label>136.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>El Jammal</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Gerfaud-Valentin</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Seve</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Jamilloux</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Inhibition of JAK/STAT signaling in rheumatologic disorders: the expanding spectrum</article-title>
          <source>Joint Bone Spine</source>
          <year>2020</year>
          <volume>87</volume>
          <issue>2</issue>
          <fpage>119</fpage>
          <lpage>129</lpage>
          <pub-id pub-id-type="pmid">31521793</pub-id>
        </element-citation>
      </ref>
      <ref id="CR137">
        <label>137.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Veale</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>McGonagle</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>McInnes</surname>
              <given-names>IB</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis</article-title>
          <source>Rheumatology (Oxford)</source>
          <year>2019</year>
          <volume>58</volume>
          <issue>2</issue>
          <fpage>197</fpage>
          <lpage>205</lpage>
          <pub-id pub-id-type="pmid">29618084</pub-id>
        </element-citation>
      </ref>
      <ref id="CR138">
        <label>138.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ghoreschi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Laurence</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>O'Shea</surname>
              <given-names>JJ</given-names>
            </name>
          </person-group>
          <article-title>Janus kinases in immune cell signaling</article-title>
          <source>Immunol Rev</source>
          <year>2009</year>
          <volume>228</volume>
          <issue>1</issue>
          <fpage>273</fpage>
          <lpage>287</lpage>
          <pub-id pub-id-type="pmid">19290934</pub-id>
        </element-citation>
      </ref>
      <ref id="CR139">
        <label>139.</label>
        <mixed-citation publication-type="other">O'Shea JJ, Kontzias A, Yamaoka K, Tanaka Y, Laurence A. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis. 2013;72 Suppl 2:ii111&#x2013;115.</mixed-citation>
      </ref>
      <ref id="CR140">
        <label>140.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>O'Sullivan</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Liongue</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Lewis</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Stephenson</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Ward</surname>
              <given-names>AC</given-names>
            </name>
          </person-group>
          <article-title>Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease</article-title>
          <source>Mol Immunol</source>
          <year>2007</year>
          <volume>44</volume>
          <issue>10</issue>
          <fpage>2497</fpage>
          <lpage>2506</lpage>
          <pub-id pub-id-type="pmid">17208301</pub-id>
        </element-citation>
      </ref>
      <ref id="CR141">
        <label>141.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hodge</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Kawabata</surname>
              <given-names>TT</given-names>
            </name>
            <name>
              <surname>Krishnaswami</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis</article-title>
          <source>Clin Exp Rheumatol</source>
          <year>2016</year>
          <volume>34</volume>
          <issue>2</issue>
          <fpage>318</fpage>
          <lpage>328</lpage>
          <pub-id pub-id-type="pmid">26966791</pub-id>
        </element-citation>
      </ref>
      <ref id="CR142">
        <label>142.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wervers</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Luime</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Tchetverikov</surname>
              <given-names>I</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Influence of disease manifestations on health-related quality of life in early psoriatic arthritis</article-title>
          <source>J Rheumatol</source>
          <year>2018</year>
          <volume>45</volume>
          <issue>11</issue>
          <fpage>1526</fpage>
          <lpage>1531</lpage>
          <pub-id pub-id-type="pmid">29961685</pub-id>
        </element-citation>
      </ref>
      <ref id="CR143">
        <label>143.</label>
        <mixed-citation publication-type="other">Ogdie A, Hur P, Liu M, et al. Impact of multidomain disease presentations on patients with psoriatic arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis registry. J Rheumatol. 2021;48(5):698&#x2013;706.</mixed-citation>
      </ref>
      <ref id="CR144">
        <label>144.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Coates</surname>
              <given-names>LC</given-names>
            </name>
            <name>
              <surname>Kavanaugh</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mease</surname>
              <given-names>PJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis</article-title>
          <source>Arthritis Rheumatol</source>
          <year>2016</year>
          <volume>68</volume>
          <issue>5</issue>
          <fpage>1060</fpage>
          <lpage>1071</lpage>
          <pub-id pub-id-type="pmid">26749174</pub-id>
        </element-citation>
      </ref>
      <ref id="CR145">
        <label>145.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Singh</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Saag</surname>
              <given-names>KG</given-names>
            </name>
            <name>
              <surname>Bridges</surname>
              <given-names>SL</given-names>
              <suffix>Jr</suffix>
            </name>
            <etal/>
          </person-group>
          <article-title>2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis</article-title>
          <source>Arthritis Rheumatol</source>
          <year>2016</year>
          <volume>68</volume>
          <issue>1</issue>
          <fpage>1</fpage>
          <lpage>26</lpage>
          <pub-id pub-id-type="pmid">26545940</pub-id>
        </element-citation>
      </ref>
      <ref id="CR146">
        <label>146.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Smolen</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Landewe</surname>
              <given-names>RBM</given-names>
            </name>
            <name>
              <surname>Bijlsma</surname>
              <given-names>JWJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update</article-title>
          <source>Ann Rheum Dis</source>
          <year>2020</year>
          <volume>79</volume>
          <issue>6</issue>
          <fpage>685</fpage>
          <lpage>699</lpage>
          <pub-id pub-id-type="pmid">31969328</pub-id>
        </element-citation>
      </ref>
      <ref id="CR147">
        <label>147.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bannuru</surname>
              <given-names>RR</given-names>
            </name>
            <name>
              <surname>Osani</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Vaysbrot</surname>
              <given-names>EE</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis</article-title>
          <source>Osteoarthritis Cartilage</source>
          <year>2019</year>
          <volume>27</volume>
          <issue>11</issue>
          <fpage>1578</fpage>
          <lpage>1589</lpage>
          <pub-id pub-id-type="pmid">31278997</pub-id>
        </element-citation>
      </ref>
      <ref id="CR148">
        <label>148.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hermann</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Lambova</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Muller-Ladner</surname>
              <given-names>U</given-names>
            </name>
          </person-group>
          <article-title>Current treatment options for osteoarthritis</article-title>
          <source>Curr Rheumatol Rev</source>
          <year>2018</year>
          <volume>14</volume>
          <issue>2</issue>
          <fpage>108</fpage>
          <lpage>116</lpage>
          <pub-id pub-id-type="pmid">28875826</pub-id>
        </element-citation>
      </ref>
      <ref id="CR149">
        <label>149.</label>
        <mixed-citation publication-type="other">Nelson AE, Allen KD, Golightly YM, Goode AP, Jordan JM. A systematic review of recommendations and guidelines for the management of osteoarthritis: the chronic osteoarthritis management initiative of the U.S. bone and joint initiative. Semin Arthritis Rheum. 2014;43(6):701&#x2013;712.</mixed-citation>
      </ref>
      <ref id="CR150">
        <label>150.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Persson</surname>
              <given-names>MSM</given-names>
            </name>
            <name>
              <surname>Sarmanova</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Doherty</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Conventional and biologic disease-modifying anti-rheumatic drugs for osteoarthritis: a meta-analysis of randomized controlled trials</article-title>
          <source>Rheumatology (Oxford)</source>
          <year>2018</year>
          <volume>57</volume>
          <issue>10</issue>
          <fpage>1830</fpage>
          <lpage>1837</lpage>
          <pub-id pub-id-type="pmid">29917100</pub-id>
        </element-citation>
      </ref>
      <ref id="CR151">
        <label>151.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McInnes</surname>
              <given-names>IB</given-names>
            </name>
            <name>
              <surname>Mease</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Kirkham</surname>
              <given-names>B</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial</article-title>
          <source>Lancet</source>
          <year>2015</year>
          <volume>386</volume>
          <issue>9999</issue>
          <fpage>1137</fpage>
          <lpage>1146</lpage>
          <pub-id pub-id-type="pmid">26135703</pub-id>
        </element-citation>
      </ref>
      <ref id="CR152">
        <label>152.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mease</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>McInnes</surname>
              <given-names>IB</given-names>
            </name>
            <name>
              <surname>Kirkham</surname>
              <given-names>B</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis</article-title>
          <source>N Engl J Med</source>
          <year>2015</year>
          <volume>373</volume>
          <issue>14</issue>
          <fpage>1329</fpage>
          <lpage>1339</lpage>
          <pub-id pub-id-type="pmid">26422723</pub-id>
        </element-citation>
      </ref>
      <ref id="CR153">
        <label>153.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McInnes</surname>
              <given-names>IB</given-names>
            </name>
            <name>
              <surname>Kavanaugh</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gottlieb</surname>
              <given-names>AB</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial</article-title>
          <source>Lancet</source>
          <year>2013</year>
          <volume>382</volume>
          <issue>9894</issue>
          <fpage>780</fpage>
          <lpage>789</lpage>
          <pub-id pub-id-type="pmid">23769296</pub-id>
        </element-citation>
      </ref>
      <ref id="CR154">
        <label>154.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mease</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>van der Heijde</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Ritchlin</surname>
              <given-names>CT</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1</article-title>
          <source>Ann Rheum Dis</source>
          <year>2017</year>
          <volume>76</volume>
          <issue>1</issue>
          <fpage>79</fpage>
          <lpage>87</lpage>
          <pub-id pub-id-type="pmid">27553214</pub-id>
        </element-citation>
      </ref>
      <ref id="CR155">
        <label>155.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nash</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Kirkham</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Okada</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial</article-title>
          <source>Lancet</source>
          <year>2017</year>
          <volume>389</volume>
          <issue>10086</issue>
          <fpage>2317</fpage>
          <lpage>2327</lpage>
          <pub-id pub-id-type="pmid">28551073</pub-id>
        </element-citation>
      </ref>
      <ref id="CR156">
        <label>156.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ritchlin</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Rahman</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Kavanaugh</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial</article-title>
          <source>Ann Rheum Dis</source>
          <year>2014</year>
          <volume>73</volume>
          <issue>6</issue>
          <fpage>990</fpage>
          <lpage>999</lpage>
          <pub-id pub-id-type="pmid">24482301</pub-id>
        </element-citation>
      </ref>
      <ref id="CR157">
        <label>157.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Deodhar</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Helliwell</surname>
              <given-names>PS</given-names>
            </name>
            <name>
              <surname>Boehncke</surname>
              <given-names>WH</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF&#x3B1; inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial</article-title>
          <source>Lancet.</source>
          <year>2020</year>
          <volume>395</volume>
          <issue>10230</issue>
          <fpage>1115</fpage>
          <lpage>25</lpage>
          <pub-id pub-id-type="pmid">32178765</pub-id>
        </element-citation>
      </ref>
      <ref id="CR158">
        <label>158.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mease</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Rahman</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Gottlieb</surname>
              <given-names>AB</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial</article-title>
          <source>Lancet</source>
          <year>2020</year>
          <volume>395</volume>
          <issue>10230</issue>
          <fpage>1126</fpage>
          <lpage>1136</lpage>
          <pub-id pub-id-type="pmid">32178766</pub-id>
        </element-citation>
      </ref>
      <ref id="CR159">
        <label>159.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Abbasi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mousavi</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Jamalzehi</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Strategies toward rheumatoid arthritis therapy; the old and the new</article-title>
          <source>J Cell Physiol</source>
          <year>2019</year>
          <volume>234</volume>
          <issue>7</issue>
          <fpage>10018</fpage>
          <lpage>10031</lpage>
          <pub-id pub-id-type="pmid">30536757</pub-id>
        </element-citation>
      </ref>
      <ref id="CR160">
        <label>160.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nikfar</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Saiyarsarai</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Tigabu</surname>
              <given-names>BM</given-names>
            </name>
            <name>
              <surname>Abdollahi</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Efficacy and safety of interleukin-1 antagonists in rheumatoid arthritis: a systematic review and meta-analysis</article-title>
          <source>Rheumatol Int</source>
          <year>2018</year>
          <volume>38</volume>
          <issue>8</issue>
          <fpage>1363</fpage>
          <lpage>1383</lpage>
          <pub-id pub-id-type="pmid">29737371</pub-id>
        </element-citation>
      </ref>
      <ref id="CR161">
        <label>161.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tavakolpour</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Alesaeidi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Darvishi</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A comprehensive review of rituximab therapy in rheumatoid arthritis patients</article-title>
          <source>Clin Rheumatol</source>
          <year>2019</year>
          <volume>38</volume>
          <issue>11</issue>
          <fpage>2977</fpage>
          <lpage>2994</lpage>
          <pub-id pub-id-type="pmid">31367943</pub-id>
        </element-citation>
      </ref>
      <ref id="CR162">
        <label>162.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Scott</surname>
              <given-names>LJ</given-names>
            </name>
          </person-group>
          <article-title>Tocilizumab: a review in rheumatoid arthritis</article-title>
          <source>Drugs</source>
          <year>2017</year>
          <volume>77</volume>
          <issue>17</issue>
          <fpage>1865</fpage>
          <lpage>1879</lpage>
          <pub-id pub-id-type="pmid">29094311</pub-id>
        </element-citation>
      </ref>
      <ref id="CR163">
        <label>163.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Genovese</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Pacheco-Tena</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Covarrubias</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Longterm safety and efficacy of subcutaneous abatacept in patients with rheumatoid arthritis: 5-year results from a phase IIIb trial</article-title>
          <source>J Rheumatol</source>
          <year>2018</year>
          <volume>45</volume>
          <issue>8</issue>
          <fpage>1085</fpage>
          <lpage>1092</lpage>
          <pub-id pub-id-type="pmid">29657147</pub-id>
        </element-citation>
      </ref>
      <ref id="CR164">
        <label>164.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mease</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Gottlieb</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>van der Heijde</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis</article-title>
          <source>Ann Rheum Dis</source>
          <year>2017</year>
          <volume>76</volume>
          <issue>9</issue>
          <fpage>1550</fpage>
          <lpage>1558</lpage>
          <pub-id pub-id-type="pmid">28473423</pub-id>
        </element-citation>
      </ref>
      <ref id="CR165">
        <label>165.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Berekmeri</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mahmood</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Wittmann</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Helliwell</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Tofacitinib for the treatment of psoriasis and psoriatic arthritis</article-title>
          <source>Expert Rev Clin Immunol</source>
          <year>2018</year>
          <volume>14</volume>
          <issue>9</issue>
          <fpage>719</fpage>
          <lpage>730</lpage>
          <pub-id pub-id-type="pmid">30118353</pub-id>
        </element-citation>
      </ref>
      <ref id="CR166">
        <label>166.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fleischmann</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Kremer</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Cush</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis</article-title>
          <source>N Engl J Med</source>
          <year>2012</year>
          <volume>367</volume>
          <issue>6</issue>
          <fpage>495</fpage>
          <lpage>507</lpage>
          <pub-id pub-id-type="pmid">22873530</pub-id>
        </element-citation>
      </ref>
      <ref id="CR167">
        <label>167.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schett</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Wollenhaupt</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Papp</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study</article-title>
          <source>Arthritis Rheum</source>
          <year>2012</year>
          <volume>64</volume>
          <issue>10</issue>
          <fpage>3156</fpage>
          <lpage>3167</lpage>
          <pub-id pub-id-type="pmid">22806399</pub-id>
        </element-citation>
      </ref>
      <ref id="CR168">
        <label>168.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Abu-Shakra</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gladman</surname>
              <given-names>DD</given-names>
            </name>
            <name>
              <surname>Thorne</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Long</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Gough</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Farewell</surname>
              <given-names>VT</given-names>
            </name>
          </person-group>
          <article-title>Longterm methotrexate therapy in psoriatic arthritis: clinical and radiological outcome</article-title>
          <source>J Rheumatol</source>
          <year>1995</year>
          <volume>22</volume>
          <issue>2</issue>
          <fpage>241</fpage>
          <lpage>245</lpage>
          <pub-id pub-id-type="pmid">7738945</pub-id>
        </element-citation>
      </ref>
      <ref id="CR169">
        <label>169.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kingsley</surname>
              <given-names>GH</given-names>
            </name>
            <name>
              <surname>Kowalczyk</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A randomized placebo-controlled trial of methotrexate in psoriatic arthritis</article-title>
          <source>Rheumatology (Oxford)</source>
          <year>2012</year>
          <volume>51</volume>
          <issue>8</issue>
          <fpage>1368</fpage>
          <lpage>1377</lpage>
          <pub-id pub-id-type="pmid">22344575</pub-id>
        </element-citation>
      </ref>
      <ref id="CR170">
        <label>170.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Willkens</surname>
              <given-names>RF</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Ward</surname>
              <given-names>JR</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis</article-title>
          <source>Arthritis Rheum</source>
          <year>1984</year>
          <volume>27</volume>
          <issue>4</issue>
          <fpage>376</fpage>
          <lpage>381</lpage>
          <pub-id pub-id-type="pmid">6712754</pub-id>
        </element-citation>
      </ref>
      <ref id="CR171">
        <label>171.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mease</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Gladman</surname>
              <given-names>DD</given-names>
            </name>
            <name>
              <surname>Collier</surname>
              <given-names>DH</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase III trial</article-title>
          <source>Arthritis Rheumatol</source>
          <year>2019</year>
          <volume>71</volume>
          <issue>7</issue>
          <fpage>1112</fpage>
          <lpage>1124</lpage>
          <pub-id pub-id-type="pmid">30747501</pub-id>
        </element-citation>
      </ref>
      <ref id="CR172">
        <label>172.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>El Miedany</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>El Gaafary</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Youssef</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ahmed</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Nasr</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Tailored approach to early psoriatic arthritis patients: clinical and ultrasonographic predictors for structural joint damage</article-title>
          <source>Clin Rheumatol</source>
          <year>2015</year>
          <volume>34</volume>
          <issue>2</issue>
          <fpage>307</fpage>
          <lpage>313</lpage>
          <pub-id pub-id-type="pmid">24794490</pub-id>
        </element-citation>
      </ref>
      <ref id="CR173">
        <label>173.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kalunian</surname>
              <given-names>KC</given-names>
            </name>
          </person-group>
          <article-title>Current advances in therapies for osteoarthritis</article-title>
          <source>Curr Opin Rheumatol</source>
          <year>2016</year>
          <volume>28</volume>
          <issue>3</issue>
          <fpage>246</fpage>
          <lpage>250</lpage>
          <pub-id pub-id-type="pmid">27022820</pub-id>
        </element-citation>
      </ref>
      <ref id="CR174">
        <label>174.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McInnes</surname>
              <given-names>IB</given-names>
            </name>
            <name>
              <surname>Nash</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Ritchlin</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis</article-title>
          <source>J Comp Eff Res</source>
          <year>2018</year>
          <volume>7</volume>
          <issue>11</issue>
          <fpage>1107</fpage>
          <lpage>1123</lpage>
          <pub-id pub-id-type="pmid">30230361</pub-id>
        </element-citation>
      </ref>
      <ref id="CR175">
        <label>175.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mease</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Choy</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Nash</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Comparative effectiveness of secukinumab and etanercept in biologic-naive patients with psoriatic arthritis assessed by matching-adjusted indirect comparison</article-title>
          <source>Eur J Rheumatol</source>
          <year>2019</year>
          <volume>6</volume>
          <issue>3</issue>
          <fpage>113</fpage>
          <lpage>121</lpage>
          <pub-id pub-id-type="pmid">31364979</pub-id>
        </element-citation>
      </ref>
      <ref id="CR176">
        <label>176.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mease</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Smolen</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Behrens</surname>
              <given-names>F</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial</article-title>
          <source>Ann Rheum Dis</source>
          <year>2020</year>
          <volume>79</volume>
          <issue>1</issue>
          <fpage>123</fpage>
          <lpage>131</lpage>
          <pub-id pub-id-type="pmid">31563894</pub-id>
        </element-citation>
      </ref>
      <ref id="CR177">
        <label>177.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McInnes</surname>
              <given-names>IB</given-names>
            </name>
            <name>
              <surname>Behrens</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Mease</surname>
              <given-names>PJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial</article-title>
          <source>Lancet</source>
          <year>2020</year>
          <volume>395</volume>
          <issue>10235</issue>
          <fpage>1496</fpage>
          <lpage>1505</lpage>
          <pub-id pub-id-type="pmid">32386593</pub-id>
        </element-citation>
      </ref>
      <ref id="CR178">
        <label>178.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Siebert</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Millar</surname>
              <given-names>NL</given-names>
            </name>
            <name>
              <surname>McInnes</surname>
              <given-names>IB</given-names>
            </name>
          </person-group>
          <article-title>Why did IL-23p19 inhibition fail in AS: a tale of tissues, trials or translation?</article-title>
          <source>Ann Rheum Dis</source>
          <year>2019</year>
          <volume>78</volume>
          <issue>8</issue>
          <fpage>1015</fpage>
          <lpage>1018</lpage>
          <pub-id pub-id-type="pmid">30297330</pub-id>
        </element-citation>
      </ref>
      <ref id="CR179">
        <label>179.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Genovese</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Durez</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Richards</surname>
              <given-names>HB</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study</article-title>
          <source>Ann Rheum Dis</source>
          <year>2013</year>
          <volume>72</volume>
          <issue>6</issue>
          <fpage>863</fpage>
          <lpage>869</lpage>
          <pub-id pub-id-type="pmid">22730366</pub-id>
        </element-citation>
      </ref>
      <ref id="CR180">
        <label>180.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kerschbaumer</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sepriano</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Smolen</surname>
              <given-names>JS</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis</article-title>
          <source>Ann Rheum Dis</source>
          <year>2020</year>
          <volume>79</volume>
          <issue>6</issue>
          <fpage>744</fpage>
          <lpage>759</lpage>
          <pub-id pub-id-type="pmid">32033937</pub-id>
        </element-citation>
      </ref>
      <ref id="CR181">
        <label>181.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Emery</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Pope</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Kruger</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Efficacy of monotherapy with biologics and JAK inhibitors for the treatment of rheumatoid arthritis: a systematic review</article-title>
          <source>Adv Ther</source>
          <year>2018</year>
          <volume>35</volume>
          <issue>10</issue>
          <fpage>1535</fpage>
          <lpage>1563</lpage>
          <pub-id pub-id-type="pmid">30128641</pub-id>
        </element-citation>
      </ref>
      <ref id="CR182">
        <label>182.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gladman</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Rigby</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Azevedo</surname>
              <given-names>VF</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors</article-title>
          <source>N Engl J Med</source>
          <year>2017</year>
          <volume>377</volume>
          <issue>16</issue>
          <fpage>1525</fpage>
          <lpage>1536</lpage>
          <pub-id pub-id-type="pmid">29045207</pub-id>
        </element-citation>
      </ref>
      <ref id="CR183">
        <label>183.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Edwards</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Blanco</surname>
              <given-names>FJ</given-names>
            </name>
            <name>
              <surname>Crowley</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)</article-title>
          <source>Ann Rheum Dis</source>
          <year>2016</year>
          <volume>75</volume>
          <issue>6</issue>
          <fpage>1065</fpage>
          <lpage>1073</lpage>
          <pub-id pub-id-type="pmid">26792812</pub-id>
        </element-citation>
      </ref>
      <ref id="CR184">
        <label>184.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kavanaugh</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mease</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Gomez-Reino</surname>
              <given-names>JJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor</article-title>
          <source>Ann Rheum Dis</source>
          <year>2014</year>
          <volume>73</volume>
          <issue>6</issue>
          <fpage>1020</fpage>
          <lpage>1026</lpage>
          <pub-id pub-id-type="pmid">24595547</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>